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Abstract
Using the in-silico approach, with ENCODE ChIP-seq data for various transcription factors 
and different cell types; we systematically compared the distance between the transcription 
factor binding site (TFBS) and the transcription start (TSS). Our aim was to determine if the 
same transcription factor binds at a different position relative to the TSS in a normal and an 
abnormal cell type. We compare distribution of distance of binding sites from the TSS; to 
make description less verbose we call this “distance” where there is no possibility of 
confusion. We used a case-control methodology where the distance between the TFBS and 
the TSS in the normal, non-cancerous or untreated cell type is the control. The distance 
between the TFBS and the TSS in the cancerous or treated cell type is the case. We use the 
distance between the TFBS and the TSS in the control as the standard. We compared the 
distance between the TFBS and the TSS in the case and the control. If the distance between 
the TFBS and the TSS in the control was greater than the distance between the TFBS and 
the TSS in the case, we can infer the following. The transcription factor in the case binds 
closer to the TSS compared to the control. If the distance between the TFBS and the TSS in 
the control is smaller than the distance between the TFBS and the TSS in the case, we can 
infer the following. The TF in the case binds further away from the TSS compared to the 
control. Our method is a screening method whereby we compare ChIP-seq data to determine 
if there is a difference in the distribution distance between the TFBS and the TSS for 
normal and abnormal cell types. We used the R package ChIP-Enrich to compare the 
distribution of distance between ChIP-seq peak and the nearest TSS. ChIP-Enrich produces a 
histogram with the number of ChIP-seq peaks at a certain distance from the TSS. The 
results indicate for some transcription factors like GM12878-cMyc and K562-cMyc there 
is a difference between the distribution of distance between the TFBS and the nearest TSS. 
cMyc has more binding sites within a distance of 1kb from the TSS in GM12878 when 
compared to K562.
GM12878-CTCF and K562-CTCF have slight differences when comparing their distribution 
of distance from the TSS. This means CTCF binds almost the same distance from the TSS in 
both GM12878 and K562. A549-gr treated with dexamethasone is interesting because with 
increase dose of dexamethasone the distribution of distance from the TSS changes as well.
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1 Introduction
Transcription factors (TF) are an important group of proteins that are essential for the process 
of transcribing DNA to RNA. Transcription factors either bind directly to DNA or bind with 
a host of other proteins to form a complex, which then binds to the DNA (Villard, 2004; 
Barrera and Ren, 2006).
How does a normal type become abnormal or cancerous? What is the difference between a 
normal and cancerous cell type? There are many reasons for a normal cell type to become 
cancerous and many differences between a normal and cancerous cell type. This study 
investigates the distance between the transcription factor-binding site (TFBS) and 
transcription start site (TSS). Could it be that a transcription factor binds closer or further 
away from the TSS, which causes the cell type to be abnormal. The aim of our study was 
to compare the distance between the TFBS and the TSS in a normal and abnormal cell type 
for the same transcription factor. We compare distribution of distance of binding sites from 
TSS; to make description less verbose we call this “distance” where there is no possibility 
of confusion.
Transcription factors bind at various distances from the transcription start site (TSS). 
However, no comprehensive study compared the distance between the TF binding site and 
the TSS in different cell types. We used an in-silico method with ChIP- seq data, and a case- 
control approach to compare the distance between the TF binding site and the TSS for the 
same TF but in two different cell types. Since we using an in-silico top- down approach, our 
starting point was the availability of ChIP-seq data for the control and case. We did not 
perform our own ChIP-seq experiments. We used ChIP-seq data from well- known 
established labs that is publicly available from ENCODE (Encode Consortium, 2011).
The centre of the ChIP-seq peak indicates the position of the TFBS. Our control is the 
distance between the TFBS and the nearest TSS in the normal or untreated cell type. Our case 
is always the distance between the TFBS and the TSS in abnormal or treated cell type. We 
use the same transcription factor in both the control and the case. For example, for the 
transcription factor CTCF, cell types GM12878 and K562. The distance between the TSS and 
the CTCF binding site in GM12878 was the control and the distance between the CTCF 
binding site and the TSS in K562 was the case. GM12878 is a normal cell type and K562 is a 
cancerous cell type.
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The unit of measurement is the number of bases. We measure distance by counting the 
number of bases between the TFBS and the TSS.
The method for calculating the distance between the TFBS and the TSS is as follows:
Let us assume GM12878-CTCF has a ChIP-seq peak with the following arbitrary BED 
coordinates, chromosome 5, start position 1000 and end position 2000. We calculate the 
centre of the ChIP-seq peak by adding to the start position the difference between the end and 
start position and we add 1 to the total.
Centre of ChIP-seq peak (GM12878-CTCF) =Start + ((end-start)/2) +1
=1000 + (2000-1000)/2 + 1 = 1501
We use 1501 to indicate the position of the CTCF binding site in GM12878.
K562-CTCF with arbitrary BED coordinates chromosome 5, start position 1300 and end 
position of 2500.
Centre of ChIP-seq peak (K562-CTCF) =Start + ((end-start)/2) +1
=1300 + (2500-1300)/2 + 1 = 1901
We used the refseq gene annotation data from University of California, Santa Cruz 
Bioinformatics (UCSC) to obtain the nearest transcription start site. We assume from the 
refseq data we find on chromosome 5 the nearest arbitrary TSS is at position 800.
We can calculate the distance between the TFBS and the nearest TSS as follows.
Distance between the TFBS and TSS (GM12878-CTCF) = Centre of ChIP-seq peak -  TSS
=1501-800
=701
Distance between the TFBS and TSS (K562-CTCF) = Centre of ChIP-seq peak -  TSS
=1901-800
=1101
We can now compare the distance between the TFBS and the TSS for GM12878-CTCF and
K562-CTCF. In the example above, we notice with K562-CTCF the distance between the
TFBS and the TSS is larger compare to GM12878-CTCF. We infer that CTCF binds further
from the TSS in K562 as compared to GM12878.
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The tool used to measure the genome wide distance between the TFBS and the TSS is ChIP- 
Enrich (Welch et al., 2014) an R (R Development Core Team,2011) library which is part of 
Bioconductor (Doerge, 2006). ChIP-Enrich is a package specifically created to get the 
distribution of distance between ChIP-seq peak and the nearest TSS.
We use a case-control methodology to compare the distance between the TFBS and the TSS 
in normal and abnormal cell types.
The reason for using a case-control approach is that we need a standard for the distance 
between the TFBS and the TSS. The control gives us an idea as to what the normal distance 
between the TFBS and the TSS is. We compare the distance between the TFBS and the 
TSS in the case and the distance between the TFBS and the TSS in the control. Based on the 
measured distances we can determine if the transcription factors in the case binds at the same 
position, closer or further away from the TSS when compared to the control.
Studies have been done looking at the binding of TF relative to the TSS (Cheng et al., 2011 ; 
Giannopoulou and Elemento, 2013); however a few short comings of these methods are the 
choice of control (Tallack et al., 2012) or only a certain distance from the TSS is investigated 
(Cheng et al., 2012).
Other studies also grouped many transcription factors together and then summarized their 
results (Wang et al., 2012).
The approach of using a case-control methodology in comparing distance between the TFBS 
and the TSS in normal and abnormal cell types is novel and we hope to obtain meaningful 
results. We have tried to use ChIP-seq data from the same labs for both the control and case 
cell type for consistency and to keep the differences between control and case as negligible as 
possible.
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Our aim of the project was to compare the distance between the TFBS and the TSS in control 
and case cell type and to determine whether there is a difference. We view the study as a 
screening method to identify whether distance between the TFBS and the TSS could be a 
factor that explains the differences between normal and abnormal cell type. If there is a 
difference between control and case, we can infer that the distance between the TFBS and the 
nearest TSS could possibly be one of many factors, which explain the difference between 
normal and abnormal cell types. If there is no difference between control and case, we can 
assume the distance between the TFBS and the nearest TSS is possible not a factor that could 
explain the difference between normal and abnormal cell type. If there is a difference 
between control and case distances, further investigation will be required. It is beyond the 
scope of this project to determine the reasons for the difference in distribution of distance 
between the TFBS and the TSS.
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2 Hypothesis and Aims
2.1 Introduction
We compare the distance between the TFBS and the TSS in a normal cell type with the 
distance between the TFBS and the TSS in an abnormal cell type using a case-control 
methodology. The distance between the TFBS and the TSS in normal cell type is the control 
distance and the distance between the TFBS and the TSS in abnormal cell type is the case 
distance. Note we use the same TF in both the control and case distances and the only 
difference between the case and control is the cell type. We use a normal or untreated cell 
type for the control distances and an abnormal or treated cell type for the case distances.
2.2 Hypothesis
Our hypothesis is there is a difference between the distance of the TFBS and the TSS in the 
control cell type and distance between the TFBS and the TSS in the case type for the same 
transcription factor.
We tested our hypothesis by looking at the distribution distance between the ChIP-seq peak 
and the TSS and comparing the distribution distances between control and the case. 
Performing a genome wide comparison we looked at specific intervals or distance from the 
TSS when comparing the control and case distances.
2.3 Aims
Our aims are the following:
1. We use ChIP-seq data to measure the distance between the TFBS and nearest the TSS 
in a normal cell type. We defined this distance as our control distance.
2. We use ChIP-seq data to measure distance between the TFBS and the nearest TSS in 
an abnormal cell type. This distance we defined as our case distance.
3. Compare the distances between the control and the case. We have three scenarios for 
the difference in distance between the control and case.
a. Control distance is greater than the case distance. The TF binds closer to the TSS 
in the case when compared to the control
b. Control distance is smaller than the case distance. The TF binds closer to the TSS 
in the control as compared to the case.
c. Control distance and case distance is the same. The TF binds at the same distance in 
control as compared to case.
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3 Literature Review
3.1 Introduction
In this chapter, we review the current literature pertaining to transcription factors and the 
binding mechanism of TF with DNA, the manner in which TF activates genes. We also 
identify various sources of biological data. A particular section of this chapter deals with 
ENCODE because the source for all our data is the ENCODE proj ect. Other sections in this 
chapter we cover include an overview of ChIP-seq and a discussion on cell types.
3.2 Overview of transcription
Chromosomes
Deoxyribonucleic acid (DNA) is the building block of nucleic material. DNA normally 
occurs as two long polymer chains. The chains consist of repeating units called nucleotides.
A single polymer chain is a DNA strand. The DNA strand has a backbone, which consist of 
alternating phosphate and sugar residues. The sugar is a two deoxyribose, pentose sugar.
The phosphate residue between the third and fifth carbon atoms of the adj acent ring, bind 
the sugars to from phosphodiester bonds, which gives the DNA strand polarity. The 
polarity in a DNA strand indicated by the 3’ (hydroxyl) end and the 5’ (phosphate) end.
Hydrogen bonds between base portion of the nucleotides and base stacking between the 
aromatic nucleobases stabilise and hold the DNA chains together. There are four bases found 
in DNA, namely thymine (T), adenine (A), quinine (G) and cytosine (C). Cytosine will pair 
with guanine and thymine with adenine (Watson and Crick, 1953; Yakovchuk et al., 2006).
The DNA packaged with specific proteins such as histones into a structure called chromatin. 
The chromatin is further compressed into nucleosome which is DNA wrapped around 8 
histone molecules. The nucleosome compressed further into a solenoid structure. The 
solenoidal structure is compressed further looping to form chromosomes.
For transcription, factors to bind to the transcription factor-binding site the DNA needs to 
be uncompressed and the correct binding site exposed for the transcription factor to bind to it. 
Chromatin remodelling is the process of uncompressing DNA and exposing the correct 
binding site for transcription factor. SWI/SNF complex acts in 3 different ways to make the 
DNA accessible. The first method is nucleosome remodelling whereby the structure of the 
nucleosome changed to allow transcription factors to bind to it. The second method,
nucleosome sliding, the DNA is exposed by the nucleosome sliding along DNA. The last 
6 | P a g e
method of nucleosome displacement involves nucleosome leaving and then binding to 
another nucleosome (Agalioti et al., 2002).
DNA can also be uncompressed by histone modification, which results in a less tight 
chromatin structure. Histone modification occurs through acetylation, which is the addition of 
an acetyl group to free amino residue in the histone molecule, which reduces its net positive 
charge. Phosphorylation and methylation are also ways to open chromatin and expose DNA 
(Smale, 2001).
Genes
A gene is a small section of DNA, which codes for ribonucleic acid (RNA) which codes a 
particular protein. Genes consists of both introns and exons and a number of distinct regions 
e.g. promoter region, control element and transcription start site (TSS). The main purpose of 
the promoter region is for proteins, which has a DNA-binding motif to bind to the DNA. A 
transcription factor (TF) is a protein, which has a specific DNA-binding domain, which allows 
it to bind to DNA (Lemon and Tjian, 2000).
A gene has the following elements:
1. Gene promotor - the gene promotor or core promoter is the area upstream between the 
TSS and including the TATA box. Polymerase II and other proteins, which is essential 
for transcription, bind in this region. The TATA box is upstream next to TSS and it is an 
AT rich sequence found in many but not all genes. The function of the TATA box is 
to accurately position the start of the TSS. Genes, which do not have TATA box, 
may contain an initiator element, which is important for detecting the TSS.
2. Upstream promoter elements - The Sp1 box and CCAAT box are normally found in 
this region, which is upstream from the TATA box. These promotor elements are 
important for transcription and if they not present or damage then no transcription will 
take place (Lee et al., 1987).
3. Regulatory elements - Glucocorticoid response element (GRE), Metal response 
elements (MRE). These elements allow genes to respond or react to specific stimuli 
(Halfon, 2006).
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4. Enhances - Sequences which is located far away from a TSS, which enhances 
promotor activity. Enhancers can occur upstream, downstream or even within the 
transcription start sites. E.g. of enhances are AP1 and AP2 (Li et al., 2006).
RNA Polymerase
RNA polymerase is an enzyme, which is responsible transcribing DNA. The types of 
RNA polymerase are RNA polymerase I, RNA Polymerase II and RNA Polymerase III. 
The three types of RNA polymerase are homologous to each other and their active site 
all occur in the second largest subunit. The three RNA polymerases are active on different 
genes and by using alpha-amanitin, which is a fungal toxin one can distinguish between 
the three different RNA polymerases. RNA polymerase cannot transcribe genes on its 
own. RNA polymerase forms stable complexes with other transcription factors, which 
allow transcription to form. Without stable complexes, no transcription can occur 
(Sentenac, 1985).
RNA polymerase I
RNA polymerase I transcribes genes encoding 5.8S, 18S and 28S ribosomal RNA. RNA 
polymerase I is not sensitive to alpha-amanitin. In Acanthamoeba, the transcription factor 
TF-1 binds to DNA at the promoter region and polymerase I will bind next to TF-1. 
Transcription can start once RNA polymerase I binds next to TF-1. As RNA polymerase I 
moves along DNA TF-1 will remain at the promoter region and be ready for next RNA 
polymerase molecule (Paule and White, 2000).
In vertebrates, the transcription factors required to form a stable complex is UBF 
(upstream binding factor), SL1 (TF-1 homolog) and RNA polymerase I. UBF binds to the 
promotor region and facilitates the binding of SL1 (Russell and Zomerdijk, 2005).
RNA polymerase II
RNA polymerase II transcribe all genes encoding for proteins and small nuclear 
RNA, which is involved in RNA splicing. RNA polymerase II is very sensitive to 
alpha- amanitin and inhibited by a dose of 1 ^ g/ml.
The transcription factor TFIID binds to DNA in the promoter region. TFIIB binds to 
TFIID. TFIIB can bind to RNA polymerase II directly. The RNA polymerase II and 
TFIIF is recruited by TFIIB. Following the binding of RNA polymerase II the 
transcription factors TFIIE, TFIIH and TFIIJ binds to the complex. TFIIH opens the
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double stranded which allows the transcription of the DNA (Zurita and Merino, 2003). 
TFIIH phosphorylates RNA polymerase II that allows transcription to begin. During 
transcription as the RNA polymerase II and TFIIH moves along DNA to copy it, TFIIA 
and TFIIH remains at the promoter region allowing other RNA polymerase II molecules 
to bind to it and start again with transcription (Hahn, 2004).
An alternative way in which RNA polymerase II transcription happen is as follows.
The transcription factors TFIIA and TFIID binds to DNA at promoter region. A 
preformed complex consisting of TFIIB, TFIIF, TFIIE, TFIIH, TFIIJ and RNA 
polymerase II forms. The preformed complex binds to TFIIA and TFIID and gene 
transcription can begin (Myer and Young, 1998).
RNA polymerase III
RNA polymerase III transcribe the 5S ribosomal RNA and transfer RNMA. RNA 
polymerase III is moderately sensitive to alpha-amanitin and inhibited by a dose of 
10^g/ml.
RNA polymerase III consists of three classes, namely class I, class II and class III. All three 
classes require TFIIIB for transcription.
Class I require TFIIIB with additional factors, TFIIIA and TFIIIC.TFIIIA and TFIIIC can 
bind directly to DNA in the promoter region however, TFIIIB require TFIIIC. The 
polymerase recognises TFIIIB and binds next to it and transcription is ready to begin.
Class II and class III does not need TFIIIA for transcription. TFIIIB, TFIIIC and the 
polymerase is all that needed for transcription (Hernandez, 1993).
Transcription is the process by which DNA is copied to form messenger RNA (mRNA), 
or as the fundamental dogma of biology states, DNA produces RNA, which produces 
protein. The transcription process consists of three phases namely initiation, elongation 
and termination.
The process of transcription can be summarised in three phases as follows. The first phase is 
the initiation phase consists of mainly identifying the core promoter region of the gene, 
assembly of the various proteins required including polymerase as well as the transcription
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factor to form a complex. Once the complex has been assembled the transcription factor will 
be the link which binds the assembled complex to the.
The second phase is the elongation phase involves transcribing of the DNA to RNA, 
replacing the thymine base with the uracil base.
The last phase is the termination phase which the completion of the transcription process.
3.3 Genomic data
The three major institutes that stores genomic data are as follow:
1) Genbank (Mrozek et al., 2013)
2) European molecular and biology lab (EMBL)
3) National Institute of Genetics, Mishima
These three institutes generally share information amongst each other and many contain the 
same information. There are various tools available to access the information from these 
databases.
To access information stored in Genbank you can use the University of California, Santa 
Cruz Bioinformatics (UCSC) Genome browser, the NCBI and ENSEMBL browsers.
3.3.1 UCSC Genome browser
The University of California, Santa Cruz Bioinformatics group produced the UCSC genome 
browser. Information displayed in the form of a track. Tracks provide a host of different 
features e.g. genes, CpG islands (areas which high a concentration of CpG (cytosine and 
guanine nucleotides)), SNP’s and predicted gene regulatory regions (Rosenbloom et al., 
2013).
3.3.2 NCBI
The National Centre of Biotechnoly information is part of the National Institutes of Health, 
which provide genomic information for organisms with complete genomic sequence 
assembly as well for organism who has no or little sequence information available. The
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browser is linked to other NCBI tools e.g. Entrez, UniGene, Online Mendelian Inheritance in 
Man, dbSNP and dbSTS.
3.3.3 ENSEMBL
ENSEMBL is a joint venture between the Sanger institute and the European Bioinformatics 
Institute (EBI). Ensembl provides a genome browser and genome information on various 
species, which includes humans, mouse and some plant species. Ensembl provides gene 
annotation data, comparative genomic data, regulation information, variation information 
(Flicek et al., 2010). Ensembl also provides information from ENCODE and data can be 
downloaded using a web browser or via application programming interface (API) using Perl 
scripts (Flicek et al., 2011).
3.4 ENCODE
Encyclopaedia of DNA Elements (ENCODE) Project’s aim is to study and understand the 
human genome in order to improve health (Encode Consortium, 2011). The ENCODE 
project was started in 2003 by the National Human Genome Research Institute (NHGRI) with 
the goal of identify and annotating all functional elements which is encoded by the human 
genome. The ENCODE proj ect is an international collaboration amongst various researchers. 
The ENCODE website has a vast amount of information and we used primarily the ChIP-seq 
data from the ENCODE to do our investigations for the project.
3.5 Overview of ChIP-seq
An in-silico method to analyze genome-wide TF binding. ChIP-seq is a method for 
identifying the genome-wide binding location of a particular TF. The ChIP-seq identifies 
peaks, which approximate the binding location of a particular TF. The ChIP-seq peak data file 
when in bed format and contains the chromosome number, start and end coordinates for the 
ChIP-seq peak.
Protein groups interact differently with the genome depending on the type of protein. There is 
three classes of proteins namely point source factors, broad source and mixed source factors. 
Point source factors generate highly localized ChIP-seq signal, which includes most 
transcription factors and indicates binding which occurs when the chromatin is open. The 
ENCODE database contains ChIP-seq information mostly on point source factors. Broad
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source factors bind to a wide genomic region e.g. chromatin marks. Mixed source factors 
bind in certain region as point source factors and other regions as broad source factors.
ChIP-seq data will combine with JASPAR or TRANSFAC motif database to identify 
transcription sites. TRANSFAC is a database, which contains information on eukaryotic DNA 
sequence elements as well as the transcription factor information (Wingender et al., 1996; 
Matys, 2003; Qian et al., 2006; Perier et al., 2000; Stegmaier et al., 2004), the transcription 
factor binding sites and DNA genome-wide binding information. The database has a 
relational architecture with two main tables namely, SITE and factor with an additional 50 
other tables linked to each other
JASPAR is an open access database for eukaryotic transcription binding profiles (Sandelin et 
al., 2004). According to Portales-Casamar et al. (2010), JASPAR is the leading open access 
database, which provides information on transcription factor binding
For a brief overview of ChIP-seq data that is available from ENCODE see Dunham et al. 
(2012). ChIP-seq allows one to do genome-wide analysis of transcription factor binding 
specificity (Hallikas et al., 2006; Kaplan et al., 2011). Numerous studies used ChIP-seq 
data from ENCODE (Encode Consortium, 2011) to identify transcription-binding sites 
(Zhang et al., 2008; Chen et al., 2012; Kulakovskiy et al., 2013a). The main objective of 
these studies has been to identify and predict transcription binding sites, motifs, epigenetic 
marks (Thomas-Chollier et al., 2012), transcription start sites and transcription binding 
specificity. ChIP-seq can be use to study evolutionary dynamics of transcription factor 
binding (Schmidt et al., 2010).
In our study, one should be cognisant of the condensed state of the DNA. ChIP-seq data 
peaks indicate possible TF binding sites and binding to these sites occurred when the 
binding site was available or accessible which occurred generally occurred when the 
chromatin was in an open state. When looking at ChIP-seq data one must always be aware 
the ChIP-seq data might not represent all binding sites due to the inaccessibility of binding 
sites which might be due to the chromatin being in a closed or condensed state (Encode 
Consortium, 2011).
3.6 Motif based analysis of TF binding sites
Statistical computational methods used to obtain transcription factor binding site information.
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These methods use ChIP-seq data and various algorithms to find motifs. The p-value is used to 
evaluate discovered motifs is accepted as a possible binding site or rej ected as being not significant.
Below is a summary of the most common motif discovery tools.
MEME (Multiple Expectation Maximization for Motif Elicitation) used for discovering 
transcription factors binding sites as well as protein domains in a group of related DNA 
sequences or proteins (Bailey and Elkan, 1994). MEME is well known and accepted for its 
motif finding ability and by using MEME we can identify the motifs associated for a 
particular TF using ChIP-seq data (Bailey et al., 2006).
Centrimo (Bailey and Machanick, 2012) is a statistical tool used to identify the distribution 
of the region of maximum enrichment within a set of binding regions. Centrimo output is a 
motif with an E-value, which indicates statistical significance of the centrally enriched region.
Centrimo can identify motifs that bind preferentially at or near the centre of the given binding 
region that occur at the peak or near the centre which indicates direct binding whilst motifs 
with no central bias which are located at the flanks of the peak normally indicate indirect or 
cooperative binding (Bailey and Machanick, 2012).
Centrimo will allow us to determine if the ChIP-seq data contain enriched motifs, binding 
specificity and directly or indirect TF binding.
T omtom is part of the MEME suite and it iused to compare a known motif against a database of 
motifs (Gupta et al., 2007).
Another useful tool is SpaMo, used to infer interactions between proteins (Whitington et 
al., 2011). SpaMo takes a motif and searches a database of motifs to find neighbouring sites 
of enrichment.
diCHIPMunk (Kulakovskiy et al., 2013b) is another tool which allows one to model 
transcription binding sites using ChIP-seq data. diCHIPMUNK transcription binding site 
model is based on an optimal dinucleotide position weighted matrices which takes into 
account correlating neighbouring nucleotides.
Another method uses the hidden Markov models (HMM)-based approach to model the 
dependence between adj acent nucleotide positions and show their method, which they called 
kmerHMM can also deduce multiple binding modes for a given TF. The authors claim the 
strength of the kmerHMM method is that it can distinguish distinct binding modes between a
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DNA-binding protein and its target sequence, which could provide biological insights on the 
subtlety of the gene regulation (Wong et al., 2013).
3.7 Cell Types
Cell types refer to the source of the DNA which particular tissue or blood used to obtain the 
cell to extract DNA. The ENCODE consortium divided the cell types into 3 tiers. The first 
tier has the highest priority and used first in experiments before the other tiers. Tier 2.5, the 
last tier has the lowest priority. Since tier 1 has highest priority, many data is available for 
cell types listed tier 1 (Rosenbloom et al., 2013).
ENCODE displays the following information for each cell type.
Each cell has a name or identifier followed by a description of the cell followed by the 
lineage, the tissue of the cell. The karyotype specified indicating whether cell obtained is 
normal or cancerous. Information provided on the gender of the person of the cell, there is 
also information on the lab, and the specific method used to extract DNA.
If one is comparing transcription binding specificity for the same species but for different cell 
types one need to be aware of differences in transcription binding specificity across cell 
types. Studies of cell type specificities of transcription factor binding sites showed general 
binding differences increase as functional and evolutionary distances increase (Handstad et 
al., 2012). When comparing transcription-binding sites for various cell types Lee et al. (2012) 
showed that there is a variable overlap ranging from about 85% below 50%. The variable 
overlap as well as evolutionary differences in evolutionary distances between control cell 
type and abnormal cell type might cause a difference in the way the transcription factors 
binds to the different cell type.
We intend comparing the ChIP-seq peaks of different cell types to determine if there is a 
difference in distance between ChIP-seq peak and the TSS in a normal and abnormal cell 
type. We interested in finding out whether the distance between the TFBS and the TSS is a 
factor, which causes the difference between the normal and abnormal cell type. Cancer cells 
are known to multiply rapidly and the difference in metabolic state between the normal and 
cancerous cell can contribute difference in binding distribution.
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We use the distance between the TFBS and the TSS in the normal non-cancerous cell type as 
a yardstick to which we compare the distance between the TFBS and the TSS in the 
cancerous cell type. We determining if the TFBS in the control is closer or further away from 
the TSS in the case.
3.8 Review studies which looked at TF-TSS binding distance
A number of studies looked at the TF-TSS binding distance. A study by Lee et al. (2012) 
compared the genome-wide transcription binding specificity of Myc, CTCF and RNA 
polymerase II. ChIP-seq data was used and to determine binding sites. The TSS was 
determined using the refseq gene annotation data from the UCSC genome browser. The 
Ensembl and Vega gene annotation set was used.
Once the TSS were determined, the data was divided into 3 regions based on the distance to 
the TSS. The first region defined as a distance ±2kb around TSS. This region named the 
promoter region. The second region, called upstream region that were defined as a distance 
of 2kb -20kb upstream from TSS. The last region named the intergenic region was defined 
a distance of > 20kb from TSS.
The result of the study indicated transcription factors positively correlated with gene density 
across the genome as well as a modest association between expression levels and increasing 
distance in the 2-20 kb region.
This study was very extensive and detailed but only looked at three transcription factors. 
Although 11 different cell types used, which included both normal and cancerous cell types 
the results of the study are not conclusive for binding distribution. Using three 3 TF and by 
looking at specific regions and clustering results gives a good overview of genome-wide 
TF binding but making specific conclusions is problematic. In addition, the study only 
looked at the upstream region for the regions greater than 2kb from TSS.
The study also looked at the occupancy of Myc, CTCF and RNA polymerase II however; the 
specific order of binding was not considered. They defined occupancy, as whether one, two or 
three of the TF was present.
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Another study by Cheng et al. (2012) looked at transcriptional regulation by looking at TF- 
binding signals around TSS and the expression level of TSS measured by different 
technologies using 12 different cell types. This study tried to predict gene expression using 
the Distribution of Distance from ChIP-seq peaks to nearest TSS. This method used a neural 
network approach to predict gene expression using a region of 100 bp from the TSS.
The results of the study indicated gene expression could be calculated by using the distance 
of the TF from the TSS.
A maj or limitation of this study is the authors only looked at a narrow region of 100 base 
pairs around the TSS.
Another study by Wang et al. (2012) used 457 ChIP-seq data sets on 119 transcription factors 
in 72 cell types to characterise the sequence features of TF binding sites and to determine the 
local chromatin environment around them. MEME-ChIP used for motif discovery and 79 
unique motifs were discovered. The ChIP-seq peaks of the TF were divided into those that 
were within 2kb (TSS-proximal) of TSS and those, which were > 2kb (TSS-distal) away from 
TSS. Motif finding performed separately on the top 500 TSS-distal and TSS-proximal 
peaks and consistent motifs found between the two sets. The result of the study found 79 
unique motifs and from this, 67motifs were present in JASPAR or TRANSFAC. The 
remaining 12 motifs were highly significant and not present in JASPAR or TRANSFAC. 
They observed a general agreement between the strength of ChIP-seq signal and motif 
content in the same ChIP-seq data set. The study looked at various other issues besides motif 
discovery. The other factors, which they looked at, were:
Comparison of bound versus unbound motif sites.
Co-binding and tethered binding between different transcription factors.
Distance and orientation preference between the sites of co-binding transcription 
factors.
Cell type specific binding of sequence specific transcription factors.
Tethered binding of non-sequence specific transcription factors.
The ChIP-seq peaks of many transcription factors flanked by positioned 
nucleosomes.
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Most transcription factors bind at GC-rich, nucleosome-depleted, and DNaseI
accessible regions.
Chromatin structure around cell-line specific TF binding regions.
This study used motifs to characterise TF binding. They compared motifs and motif-to-peak 
distances for two regions namely a ± 150 bp and the flanking ± 300 bp regions. Unlike the 
previous studies, which looked specifically at the distribution of ChIP-seq peaks this 
study, focused mainly on motifs to investigate TF binding specificity.
A study by Tallack et al. (2012) used ChIP-seq data and mRNA expression data to investigate 
KLF1 binding. They also looked at the binding specificity of KLF1 relative to TSS. They 
found an overrepresentation of the CACC motif and CCAAT box. The distances between 
TSS and KLF1 ChIP-seq peaks for both KLF1 activated and repressed genes were calculated 
and compared to a control. The results for the repressed genes indicated the expression 
lowered and the ChIP-seq peak is closer to the TSS. The activated genes and the controls 
differed significantly but no mention was made by the authors on how this affected the 
KLF1-TSS distance. It is not clear how the authors obtained the controls and the method 
described when selecting samples for the controls indicated samples were not randomly 
selected but rather based on the Distribution of Distance from ChIP-seq peaks to nearest TSS. 
Generally, knock out genes are used in RNA expression studies as controls however 
knockout genes are not a suitable control for ChIP-seq studies because there is no ChIP-seq 
signal for the for the knocked-out genes.
Tallack et al. (2012) also looked at the KLF1 cooperation in vivo with GATA1, TAL1 and 
P300. They found KLF1 would bind with GATA1/TAL1 to recruit P300. They also 
compared the distance of ELK1-P300 to TSS with the distance of ELK1 to TSS and found 
that generally ELK1-P300 is closer to the TSS compared to ELK1 only. They do not 
mention which part of the ELK1-P300 complex is closest to TSS and whether the preferred 
binding distribution is upstream or downstream
Joshi et al. (2012) conducted the relationship between different types of breast cancer and 
the TSS. The authors looked at the promoter region, which they defined as the region, 
which has a distance -500bp to 100bp from the TSS They used the transcription factor­
binding site (TFBS) matrix concept to study transcription factor binding in the promoter 
region. The TFBS matrix is a group of weighted matrices, which corresponds to the same 
family of transcription factors, or transcription factors, which has similar functions.
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Genomatix
RegionMiner tool (Genomatix) used to calculate the TFBS family over represented motifs. 
The conclusion of the study was the promoter region for each cancer (or patient sub group) is 
distinct.
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4 Methodology
4.1 Introduction
This chapter describes how we obtained the data and the methods used to calculate the TFBS 
and the TSS distance. We downloaded ChIP-seq data from ENCODE and added column 
headers to ChIP-seq files. ChIP-Enrich, which is a Bioconductor package, used to plot 
histograms of the distance between the TFBS and the TSS. We calculated the distance 
between the TFBS and the TSS separately for control and case.
4.2 Downloaded the ChIP-seq data from the ENCODE website
ChIP-seq data for various transcriptions factors for the GM12878 and K562 cell types 
downloaded. GM12878 is a B-lymphoblastoid (normal) cell type and K562 is chronic 
myelogenous/erythroleukemia (cancer) cell type. We downloaded ChIP-seq data for 
transcription factors, which had both GM12878, and K562 ChIP-seq data available. We 
also downloaded ChIP-seq data for transcription factors that were treated with interferon 
and dexamethasone. In some cases, no untreated ChIP-seq data is available but we included 
it in the study and we compared the treatment time or different doses to each other. The 
reason for including ChIP-seq data with no control was for interest sake and to see whether 
treatment caused a difference in distribution distance between the TFBS and the nearest TSS. 
We assumed since the data was obtained from ENCODE and from well-known established 
labs the ChIP-seq data had minimal errors.
All data downloaded from the following URL:
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgTFbsUniform/
4.3 Distribution of Distance from ChIP-seq peaks to the nearest TSS 
histogram
To calculate distance between the TFBS and the TSS we use ChIP-Enrich (Welch et al., 
2014), an R package which is part of Bioconductor. ChIP-Enrich has a function called 
plot_distance_to_tss, which calculates the distance between the TFBS and the nearest TSS for 
ChIP-seq peaks. The results summarized as a histogram plot, which shows the distribution 
of distance of ChIP-seq peaks to nearest TSS. One can use the original peak files was 
downloaded from ENCODE however if one is using a bed format file then the file must 
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have column headings. If using a 3-column bed format file then the column headings should 
be: “chrom”, “start” and “end”. If additional columns present in data set then one can name 
these columns with any name, the program only requires the first three columns to have the 
specified name of “chrom”, “start” and “end”.
The workflow for plotting a histogram using R and the ChIP-Enrich package is as follows:
1. Load chipenrich library
2. Load chipenrich data files
3. peak=read.table (file=path and name of input file,header=TRUE)
4. plot_dist_to_TSS (peaks=peak,genome ='hg19')
4.4 Conclusion
The package ChIP-Enrich is a straight forward and easy to use. The histogram output from 
ChIP-Enrich makes it easy to visually compare the genome wide distribution distance 
between the TFBS and the nearest TSS for both control and case distances. The histogram 
shows the distance between the TFBS and the TSS for various intervals, which makes it 
easier to compare and to see the percentage of the TFBS at a particular distance from the 
TSS.
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5 Results
5.1 Introduction
In this chapter, we present the results for the data we analysed. The results of ChIP-Enrich is 
a histogram plot, which shows the distribution of distance from ChIP-seq peaks to nearest 
TSS. Although we are using a case-control methodology we have included ChIP-seq data 
where there is no control ChIP-seq data available, for example, K562-stat1 treated with 
interferon for 30min and 6 hrs. In this scenario, we do not have untreated K562-stat1 ChIP- 
seq data therefore; we compare the 30min and 6hrs ChIP-seq data to each other. We include 
these data for interest sake and to see if there is a notable difference between the distance of 
the TFBS and the TSS for the 30min and 6hr interferon treatment.
5.2 Gm12878-cMyc and K562-cMyc
5.2.1 Number of ChIP-seq peaks
14000
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No of ChIP-seq peaks
KS62 GM12878
Figure 5-1 GM12878-cMyc (Control) and K562-cMyc (Case)
The values in figure 5-1 indicate there are almost 3 times more cMyc binding sites in the 
K562 cell type as compared to the GM12878 cell type.
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5.2.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
Distribution of Distance from Peaks to Nearest TSS Distribution of Distance from Peaks to Nearest TSS
Distance to TSS (kb) Distance to TSS (kb)
Figure 5-2 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Uta.
Figure 5-2 indicates GM12878-cMyc has a higher percentage of the TFBS in the region 
where distance between the TFBS and the TSS is less than 1kb compared to K562-cMyc. The 
difference between GM12878 and K562 is significant in the 0.1 to 1kb interval. Where the 
distance between the TFBS and the TSS is greater than 1kb, GM12878-cMyc has a lesser 
percent of the TFBS when compared to K562-cMyc. We conclude, cMyc in GM12872 has a 
large number of the TFBS close to the TSS and K562 has more TFBS further away from the 
TSS.
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5.3 Gm12878-CTCF and K562-CTCF
5.3.1 Number of ChIP-seq peaks
Figure 5-3 GM12878-CTCF (Control) and K562-CTCF (Case)
Figure 5-3 shows K562-CTCF has slightly more ChIP-seq peaks compared to GM12878- 
CTCF
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5.3.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
Distribution of Distance from Peaks to Nearest TSS Distribution of Distance from Peaks to Nearest TSS
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Figure 5-4 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Uta.
Figure 5-4 indicates for both GM12878-CTCF and K562-CTCF the distribution of distance 
from ChIP-seq peak to the nearest TSS is very similar.
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5.4 K562-cJun treated with interferon alpha
We investigate the binding distribution of cJun in the K562 cell type, which was treated with 
interferon (Ifn) alpha for 30minutes and 6hr respectively. The distances between K562- cJun 
and the TSS that were not treated with interferon was used as the control and distances 
between K562-cJun and the TSS treated with interferon was used as case.
5.4.1 Number of ChIP-seq peaks
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Figure 5-5 K562-cJun untreated (Control) and K562-cJun treated with interferon alpha 
for 30min and 6hrs (Case)
Figure 5-5 indicates K562-cJun treated with interferon alpha for 6hrs have fewer ChIP-seq peaks 
when compared to the untreated K562-cJun. The untreated K562-cJun cell type have almost the same 
number of ChIP-seq peaks as the K562-cJun treated for 30min.
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5.4.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Distance to T S S  (Itb) Distance to TSS (kb) Distance to TSS (kbi
Figure 5-6 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
Figure 5-6 indicates K562-cJun, which is untreated, and the K562-cJun treated with interferon 
alpha for 30 min have a similar distribution of distance from the cJun peaks to the nearest 
TSS. When the distance between the cJun site and the TSS is less than 1kb, K562-cJun 
treated with interferon alpha for 6hrs has a lesser percent of peaks when compared to the 
untreated K562-cJun. The K562-cJun treated with interferon alpha has a greater percent of 
ChIP-seq peaks when the distance between the cJun site and the TSS is greater than 1kb 
when compared to the untreated K562-cJun.
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5.5 K562-cJun treated with interferon gamma
We investigate the binding distribution of cJun in the K562 cell type, which has been treated 
with interferon gamma for 30minutes and 6hr respectively. The distance between the cJun 
site and the TSS for K562-cJun that were not treated with interferon gamma was used as the 
control. The distance between K562-cJun and the TSS, which has been treated with interferon 
gamma, was used as case.
5.5.1 Number of ChIP-seq peaks
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Figure 5-7 K562-cJun untreated (Control) and K562-cJun treated with interferon 
gamma for 30min and 6hrs (Case)
Figure 5-7 indicates K562-cJun treated with interferon gamma for 30mins have a similar ChIP-seq 
distance distribution as the untreated K562-cJun. The K562-cJun 6hr gamma interferon treated cells 
have a fewer number of ChIP-seq peaks when compared to the untreated K562-cJun.
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5.5.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Figure 5-8 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
Figure 5-8 indicates the K562-cJun treated for 30min have fewer TFBS to the TSS when the 
distance between cJun site and the nearest gene is less than 1kb. K562-cJun treated with 
interferon gamma for 6hrs have significant fewer TFBS when the distance between cJun site 
and nearest gene is less than 1kb. When the distance between cJun site and the nearest TSS is 
greater than 1kb one finds more cJun binding sites further away from a TSS with increase 
treatment time.
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5.6 K562-cMyc treated with Ifn alpha for 30min and 6hrs
5.6.1 Num ber of ChIP-seq peaks
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Figure 5-9 K562-cMyc untreated (Control) and K562-cMyc treated with Ifn alpha for 30 min and 6 hrs (Case)
Figure 5-9 indicates the number of ChIP-seq peaks increases with increase interferon 
treatment time when compared to the untreated K562-cMyc. K562-cMyc treated for 6hrs 
with interferon alpha has double the amount of ChIP-seq peaks when compared to the 
untreated K562-cMyc.
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5.6.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Figure 5-10 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
In figure 5-10, we see the untreated K562-cMyc has a higher percentage of the TFBS 
when the distance between the TFBS and nearest gene is less than 0.1kb when compared 
to the 30min and 6hrs interferon alpha treated K562-cMyc. When the distance between the 
TFBS and the TSS > 0.1kb the distribution of distance of cMYc to the nearest TSS for 
untreated K562-cMyc is similar to both 30min and 6hrs interferon alpha K562-cMyc 
treated
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5.7 K562-cMyc treated with Ifn gamma for 30min and 6hrs
5.7.1 Num ber of ChIP-seq peaks
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Figure 5-11 K562-cMyc untreated (Control) and K562-cMyc treated with Ifn gamma for 30min and 6hrs (Case)
Figure 5-11 indicates K562-cMyc interferon gamma treated have more TFBS compared to 
the K562-cMyc which did not receive any treatment. The amount of ChIP-seq peaks decrease 
with increase treatment time.
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5.7.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Figure 5-12 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
Figure 5-12 indicates when the distance between cMyc and the TSS is less than 1kb, the 
untreated K562-cMyc has a higher percentage of ChIP-seq peaks than the 30min and 6hrs 
interferon gamma treated K562-cMyc. When the distance between cMyc and the TSS of 
nearest gene is greater than 1kb, K562-cMyc treated with interferon gamma has a higher 
percentage of the TFBS when compared to the untreated K562-cMyc.
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5.8 K562-Irf1 treated with Ifn alpha and gamma 30min and 6hrs
5.8.1 Number of ChIP-seq peaks
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Figure 5-13 K562-Irf1 treated with Ifn alpha and gamma for 30min and 6hrs
Figure 5-13 indicates an inverse relation between K562-Irf1 alpha and K562-Irf1 gamma 
treatment. The increase interferon alpha treatment time for K562-Irf1 cause’s increase in the 
number of ChIP-seq peaks and with interferon, gamma treatment the increase treatment time 
causes a decrease in the number of ChIP-seq peaks.
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5.8.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Figure 5-14 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
Figure 5-14 indicates there is not much difference between the distributions of distance from 
Irf1 to the nearest TSS for the K562-Irf1 interferon alpha treated. There is a significant 
difference in distribution of distance of Irf1 to the nearest TSS for K562-Irf1 treated with 
interferon gamma. When the distance between Irf1 and the nearest TSS is less than 1kb, 
K562-Irf1 treated for 6hrs with interferon gamma has a higher percentage of ChIP-seq peaks 
in this region, when compared to K562-Irf1 30min interferon gamma treated. When distance 
between Irf1 and nearest gene is between 10 and 50kb the 30min interferon gamma, 
treated cells have more TFBS in this region when compared to the 6hrs. The distribution 
distance for
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the 30min and 6hrs alpha interferon treatment and the 30min gamma interferon treatment 
looks similar.
5.9 A549-Gr treated with Dexamethasone (dex)
5.9.1 Number of ChIP-seq peaks
No of ChIP-seq peaks
500pm 5nm 50nm lOOnm
dex treatment dose
Figure 5-15 A-549 treated with various doses of dexamethasone
Figure 5-15 shows as the dose increase the amount of TFBS increase and then after the 50nm 
dose the TFBS decrease which could mean after 50nm saturation is reached and the increase 
dose no longer have any effect.
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5.9.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Figure 5-16 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Haib.
Figure 5-16 shows as the dose of dexamethasone increase more TFBS occur further away 
from the TSS with A549-Gr treated with dexamethasone 100nm being the exception. A549- 
Gr treated with dexamethasone 100nm has a higher percentage of the TFBS closer to a TSS 
within a distance of 1kb compared to the others. Interestingly most of the TFBS occurs far 
away from a TSS at a distance of greater than 5Kb.
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5.10 K562-stat1 treated with Ifn alpha and gamma
5.10.1 Number of ChIP-seq peaks
No of ChIP-seq peaks
Figure 5-17 K562-stat1 treated with Ifn alpha and gamma for 30min and 6hrs
Figure 5-17 shows there is not much difference between the 30min and 6hrs interferon 
treatment. The number of ChIP-seq peaks are small for both alpha and gamma interferon 
treatment.
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5.10.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
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Figure 5-18 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
Figure 5-18 shows similar distribution of distance between ChIP-seq peaks and the nearest TSS for 
both K562-stat1 treated with interferon alpha for 30min and 6hrs.
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Distribution of Distance from Peaks to Nearest TSf Distribution of Distance from Peaks to Nearest TSS
Distance to TSS (kb) Distance to TSS (kb)
Figure 5-19 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
F igure 5-19 shows similar distribution of distance between ChIP-seq peaks and the nearest TSS for 
both K562-stat1 treated with interferon alpha for 30min and 6hrs.
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5.11 K562-stat2 treated with Ifn alpha
5.11.1 Number of ChIP-seq peaks
Figure 5-20 K562-stat2 treated with Ifn alpha for 30min and 6hrs
Figure 5-20 shows increasing the treatment time of interferon alpha causes an increase in the 
number of ChIP-seq peaks. The number of ChIP-seq peaks is relatively small the increase 
peaks with increase treatment time might not be significant.
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Distribution of Distance from Peaks to Nearest TSS Distribution of Distance from Peaks to Nearest TSS
5.11.2 Distribution of Distance from ChIP-seq peaks to the nearest TSS
Distance to TSS (kb) Distance to TSS (kb)
Figure 5-21 distance between the TFBS and the TSS. Percentage binding in the various regions. Data from Sydh.
Figure 5-21 shows the distribution of distance between the 30min and 6hrs is similar.
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6 Discussion
6.1 Introduction
In this chapter, we discuss and analyse the results obtained from chapter 5. As we are a top- 
down approach, we now try and make sense of the results we obtained in the previous chapter. 
We reviewed the literature specifically looking at the distance the TF binds from the TSS and 
provide a brief overview of the various transcription factors. Finally, we compared our 
results with results obtained from the literature however, as mentioned before none of the 
studies used a case-control approach but where results were available for some of the cell 
types and transcription factors we used it.
6.2 Gm12878-cMyc and K562-cMyc
6.2.1 Background
Myc, formerly known as cMyc is a transcription factor which is known to be involved in cell 
differentiation, apoptosis, progression ,cell growth, chromosomal instability, DNA repair and 
metabolism (Dang, 2012; Gardner et al., 2002; Lee et al., 2012). Myc plays a role in tumour 
initiation as well tumour maintenance.
Knockout of Myc in cancer cells caused a reduction in proliferation and in some instances, 
apoptosis was induced. Myc has been linked to T-cell leukaemia via the Notch1 pathway.
The Myc protoncogene is regulated both upstream by the far upstream element (FUSE) and 
downstream by TCF.
According to Lee et al. (2012), Myc had 45 % to 75 % of its binding sites within a distance 
of 2KB around the TSS and Myc found in promoter rich CpG islands, which indicates Myc 
regulates genes, by binding to proximal promoters to a diverse group of gene targets across 
various cell types. Myc also had an overrepresentation of bidirectional promoters in the 2kb 
interval around the TSS. Myc when bound to the bidirectional promoter will activate both 
genes irrespective of the distance of the Myc binding from the TSS.
Myc caused an increased in target gene expression levels when binding occurred upstream 
only and Myc binding did not bind to the promoter region of target gene. Myc binding at 
both promoter and upstream region of target gene resulted in decreased expression level of 
target gene.
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6.2.2 Analysis
From figure 5.2, we see at a distance of less than 1kb away from a TSS we find more 
GM12878-cMyc peaks when compared to K562-cMyc. GM12878-cMyc have about 75% of 
its TFBS within a distance of 1kb from a TSS and K562-cMyc have about 56% of its TFBS 
in the same region. K562-cMyc have more TFBS where distance between the TFBS and the 
TSS is greater than 1kb when compared to GM12878-cMyc.
Also of interest is K562-cMyc has about 3 times more ChIP-seq peaks compared to 
GM12878-cMyc as shown in figure 5-1.
Our results for the binding sites around 1kb region around TSS are in line with Lee et al. 
(2012) which found 45% to 75 % of cMyc binding sites within a distance of 2kb from the 
TSS.
6.3 Gm12878-CTCF and K562-CTCF
6.3.1 Background
cMyc and CTCF have similar function i.e. cell growth and development and chromatin 
organisation (Macquarrie et al.,2011).
According to Filippova et al. (2002), CTCF binds to the cMyc promoter region that is 2kb 
upstream from the TSS.
It is known human CTCF can bind to 4 different promoter regions of cMyc namely 2kb and 
0.6 kb from a TSS upstream and two promoter regions downstream from a TSS (Fiorentino 
and Giordano, 2012).
The cMyc-CTCF interaction can be summed up as follows. The expression of cMyc activates 
CTCF. Once CTCF activates, it will negatively regulate cMyc. CTCF binds to the promoter 
region of cMyc, which restrict the expression of cMyc, and if CTCF binds to other regions 
excluding promoter region then CTCF will increase cMyc gene expression.
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6.3.2 Analysis
Figure 5-4 indicates GM12878-CTCF and K562-CTCF have similar distribution of distance 
from ChIP-seq peaks to nearest TSS.
GM12878-CTCF and K562-CTCF have more than 50% of its binding sites at a distance 
greater than 10kb form the TSS. In the 1kb distance from the TSS both GM12878-CTCF and 
K562-CTCF, have approximately 10% of their binding sites. GM-CTCF binds to cMyc 
promoter region therefore we need to look at CTCF in conjunction with cMyc.
The number of ChIP-seq peaks for GM12878-CTCF and K562-CTCF as shown in figure 5-3 
is very similar (56058 vs. 48916).
CTCF activated by cMyc and negatively regulates cMyc; we need to look at CTCF and 
cMyc.
K562-CTCF has approximately 5 times more ChIP-seq peaks compared to K562-cMyc. 
GM12878-CTCF has approximately 13 times more ChIP-seq peaks when compared to 
GM12878-cMyc.
cMyc has more than 50% of its binding sites within 1kb from TSS while CTCF has 
approximately 10%. CTCF has more binding sites compared to cMyc we can assume that 
CTCF will bind to cMyc in the promoter region as indicated by (Fiorentino and Giordano, 
2012).
Of interest is the 50% CTCF binding sites that occur at a distance of greater than 10kb 
from the TSS. cMyc does not have such a large number of binding sites at a distance greater 
than 10kb from the TSS.
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6.4 Interferon, JAK, STAT, cJun and Irf1
6.4.1 Background
Interferon is a member of the cytokines family and involved in anti-viral cellular response 
and with cell growth. Interferon is classified into two categories namely Type I and Type II. 
Interfon alpha (Ifn a) is classified as a type I interferon and interferon gamma (Ifn y) is a type 
II interferon (Vera et al., 2011; Pitha, 1998).
Ifn a is used for the treatment of various cancers especially blood related cancers and Ifn y is 
used to treat acute infections.
The difference between type I and type II interferon is the particular cell receptor to which 
the interferon binds. Ifn a binds to the interferon alpha receptor and Ifn y binds to the 
interferon gamma receptor. Interferon alpha and gamma receptor have subunits which 
interact with a specific member of Janus activated kinase (JAK).
Type I interferon cell receptor units will bind to either Tyrosine Kinase-2 or JAK1 and type II 
interferon cell receptors will bind to JAK1 and JAK2. The binding of interferon to cell 
receptors signals the phosphorylation and activation of the applicable JAK member.
Once JAK has been activated this signals the activation and phosphorylation of various 
STAT (Signal Transducers and Activators of Transcription). The STAT form dimers, which 
initiate transcription by binding to the promoter region of interferon-stimulated genes. Type I 
interferon form an ISGfr3 (interferon stimulated gene factor 3) complex which consists 
phosphorylated STAT1, STAT2 and Irf9.
The purpose of ISGrf3 is to bind to the interferon stimulated response element, which is 
present in the promoter region of the interferon-stimulated genes. The binding of ISGR3 to 
the interferon stimulated response element initiates transcription in these genes (Khodarev et 
al. 2012).
Interferon alpha also causes a prolonged activation of c-Jun NH2-terminal kinases, which 
causes a potential decrease in the mitochondrial membrane. Interferon alpha activated c-Jun 
NH2-terminal kinases through the activation of PKC-S signaling which resulted in TRAIL
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apoptosis (Yanase et al., 2012).
ISGrf3 can also bind to an interferon gamma activated site, which is also present in the 
promoter regions of interferon-stimulated genes which also initiates activation of the gene 
when binding occur.
The Type II interferon cell receptors will bind to JAK1 and JAK2 to STAT1 homodimers, 
which will bind to Ifn gamma, activated sites on the promoter of interferon-stimulated genes. 
The Type II interferon mechanism also regulates also the phosphorylation of STAT1 
(Andrews et al., 1987).
Interferon gamma activation of c-Jun can be summarized by the following pathway:
Ifn gamma -> Jak1/2 -> MEK 1/2 -> Erk 1/2 -> c-Jun -> AP-1 -> iNos
The above pathway indicates c-Jun is important in the formation of AP-1 and the activation 
of c-Jun is not dependent on STAT1; however, c-Jun is dependent on interferon gamma 
(Gough et al., 2007; Chesler and Reiss, 2002).
Irf1 (Interferon release factor 1) is activated by Interferon alpha and gamma by STAT1 and 
NF-KB through the JAK/STAT pathway (Kramer and Heinzel, 2010).
6.4.1.1 K562-cMyc treated with interferon.
cMyc is known to be involved in cell proliferation and the deregulated expression of cMyc 
leads to uncontrolled cell proliferation and generally cancer has an increase in cell 
proliferation cancer one would expect to find an increase in the expression cMyc (Dang, 
2012).
Interferon regulates cMyc at the RNA level and mRNA and treatment with interferon a and 
interferon P resulted in the decreased expression of cMyc-mRNA. Interferon y treatment 
decreased the v-cMyc-Max heterodimer complex level, which directly affects the transcription 
mechanism of cMyc (Hu et al., 2005; Chesler & Reiss, 2002).
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According to Dani et al. (1985), Daudi cells were treated with interferon a2 and P did not 
alter the rate of transcription cMyc but altered the half-life of cMyc-mRNA, which caused 
decreased expression levels of cMyc-mRNA.
6.4.2 K562-cJun treated with interferon alpha and gamma
6.4.2.1 K562-cJun treated with Ifn alpha for 30min and 6hrs
Figure 5-5 indicates an increase in the interferon alpha treatment time of K562-cJun of 30 
minutes and 6hrs causes a drop in the number of ChIP-seq peaks. The K562-cJun treated for 
6hrs has 5218 ChIP-seq peaks compared to K562-cJun untreated, which has 9848.
Figure 5-6 indicates in the less than 1kb distance, the control (K562-cJun untreated) has 
19.4% TFBS, the 30min Ifn alpha treatment has 22.4% and the 6hr treatment has 12% TFBS. 
K562-cJun has more than 33% of its TFBS in the 10-50kb interval for the control and treated 
samples. At a distance of greater than 10kb from the TSS the control has 55.1%, the 30min 
treated sample has 54.3% and the 6hr sample has 61.7% TFBS. The increased treatment time 
of 6hrs not only causes less ChIP-seq peaks but also fewer TFBS occur in the less than 1kb 
distance. However, in the greater than 10kb distance the 6hr sample has more TFBS 
compared to the control and 30min.
cJun regulates cell progression, apoptosis and therefore the down regulation of K562-cJun by 
Ifn cause the cancer cells not to progress normally (Lopez-Bergami et al., 2005).
6.4.2.2 K562-cJun treated with Ifn gamma for 30minutes and 6hrs
Figure 5-7 indicates an increase in the interferon gamma treatment time of K562-cJun of 30 
minutes and 6hrs causes a slight drop in the number of ChIP-seq peaks. The control has 9848, 
the 30min 8587 and 6hr has 6596 ChIP-seq peaks.
Figure 5-8 indicates in the less than 1kb distance from TSS, the control (K562-cJun 
untreated) has 19.4% binding sites, the Ifn gamma 30min has 10.9% and 6hr Ifn gamma 
treated 8.2%. More than 34% binding sites occur in the 10-50kb distance from the TSS for 
the control and Ifn gamma treated samples. In the greater than 10kb distance, the number of 
TFBS for the control is 55.1%, 30min Ifn gamma treated 62.8% and 6hr treated 65.6%.
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We conclude an increase in Ifn gamma treatment time cause cJun to have fewer binding sites 
close to the TSS in the 1kb interval. An increase in Ifn gamma treatment time causes binding 
away from promoter region with more TFBS at a distance of greater than 10kb from the TSS.
K562-cJun without treatment and with treatment generally have more than 55% of its binding 
sites at distance of 10kb from the TSS. The increased treatment time causes a decrease in the 
promoter region binding and an increase in the distal binding from the TSS.
cJun regulates cyclin which is required by cells for cell progression and therefore the down 
regulation of K562-cJun by Ifn cause the cancer cells not to progress (Lopez-Bergami et al., 
2005). We assume the Ifn gamma treatment causes cJun to bind further away from the 
promotor region, which causes the cancer cells not to progress.
6.4.3 K562-cMyc treated with Ifn alpha and gamma for 30min and 6hrs
6.4.3.1 K562-cMyc treated with Ifn alpha 30min and 6hrs
Figure 5-9 indicates an increase in the interferon alpha treatment time of K562-cMyc from 30 
minutes to 6hrs causes a corresponding increase in the number of ChIP-seq peaks. The 
control (K562-cMyc-untreated) has fewer ChIP-seq peaks when compared to the 30min and 
6hr Ifn alpha treated K562-cMyc. The 6hr treated sample has double the amount of peaks 
compared to the control.
From figure 5-10, the number of TFBS in the less than 1kb for the control is 58.6%, the 
30min treated has 52.7% and the 6hr treated has 49.8%. In the greater than 1kb region the 
number of binding sites for the control is 41.4%, the 30min treated 47.7% and the 6hr 
treatment has 50.3%.
Increase in treatment of Ifn alpha times causes increase in the number of ChIP-seq peaks and 
a decrease in the number of TFBS in the promoter region, as well as an increase in the 
number of TFBS that binds further away from the TSS.
According to Andrews et al. (1987), Ifn alpha inhibits cell proliferation and therefore the 
increase in the number of ChIP-seq peaks will prevent proliferation of K562 cells.
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6.4.3.2 K562-cMyc treated with Ifn gamma 30min and 6hrs
Figure 5-11 indicates an increase in the interferon alpha treatment time of K562-cMyc from 
30 minutes to 6hrs causes a corresponding increase in the number of ChIP-seq peaks. The 
control (K562-cMyc-untreated) has fewer ChIP-seq peaks when compared to the 30min and 
6hr Ifn alpha treated K562-cMyc. The 6hr treated sample has double the amount of peaks 
compared to the control.
From figure 5-10, the number of TFBS in the less than 1kb for the control is 58.6%, the 
30min treated has 52.7% and the 6hr treated has 49.8%. In the greater than 1kb region the 
number of binding sites for the control is 41.4%, the 30min treated 47.7% and the 6hr 
treatment has 50.3%.
Increase in treatment of Ifn alpha times causes increase in the number of ChIP-seq peaks and 
a decrease in the number of TFBS in the promoter region, as well as an increase in the 
number of TFBS that binds further away from the TSS.
6.4.4 K562-Irf1 treated with Ifn alpha 30min and 6hrs
6.4.4.1 K562-Irf1 treated with Ifn alpha 30min and 6hrs
Untreated ChIP-seq data not available therefore compared the 30min data to the 6hr data.
Figure 5-13 indicates for Ifn alpha the number of peaks increase with increase treatment time. 
#0min treated Ifn alpha has 2849 ChIP-seq peaks and 6hr has 41690 ChIP-seq peaks. Ifn 
gamma treatment causes a decrease in the number of ChIP-seq peaks with increase treatment 
time.
Figure 5-14 shows in the less than 1kb distance from the TSS, the 30min Ifn alpha has 11.9% 
and the 6hr Ifn alpha has 10.9% TFBS. The 30min Ifn gamma has 22% and the 6hr has 
64.8% of its TFBS in the less than 1kb distance from the TSS.
In the greater than 10kb distance from the TSS, Ifn alpha treated for 30min has 64.76% and 
the 6hr has 64.8% of its TFBS. In the greater than 10kb distance from the TSS, Ifn gamma 
treated for 30min has 54.6% and the 6hr has 20.6% of its TFBS.
The big difference between Ifn alpha 30min and 6hr treatment is the number of ChIP-seq 
peaks. The distribution of distance between ChIP-seq peak and the TSS is similar for the Ifn 
alpha 30min and 6hr treatment.
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With Ifn gamma treatment there is a difference in the number of ChIP-seq peaks between the 
30min and 6hr treatment. The 30min Ifn gamma treatment has fewer TFBS close to the TSS 
compared to the 6hr treated sample. The 30min Ifn gamma treated sample has more TFBS in 
the greater than 10kb distance from the TSS compared to the 6hr treatment.
6.4.5 K562-stat1 treated with Ifn alpha and gamma for 30min and 6hrs
6.4.5.1 K562-stat1 treated with Ifn alpha and gamma for 30min and 6hrs
We do not have untreated K562-stat1 ChIP-seq data and therefore we will compare the 30min 
data to the 6hr data.
Looking at Figure 5-17, we notice the number of ChIP-seq peaks are very little. K562-stat1 
treated with Ifn alpha causes a slight increase in the number of ChIP-seq peaks with increase 
treatment time. Ifn treatment corresponds to a slight decrease in the number of ChIP-seq 
peaks with increased treatment time.
Figure 5-18 indicates in the less than 1kb distance from the TSS, Ifn alpha 30min has 36.9% 
and Ifn alpha 6hr has 37 % TFBS. Ifn alpha in the greater than 10kb distance from the TSS, 
the 30min has 39.3% and the 6hr has 43.2% TFBS.
Figure 5-19 indicates in the less than 1kb distance from the TSS, Ifn gamma 30 min has 
15.8% and the 6hr has 22.2% TFBS. In the greater than 10kb distance from the TSS, Ifn 
gamma 30min has 56.6% and the 6hr has 49.7% TFBS.
Ifn alpha activates Statl because it’s part of the Ifn alpha JAK stat pathway (Li, 2008).
Ifn alpha treatment has more TFBS closer to the TSS compared to the Ifn gamma treatment. 
Ifn gamma has more TFBS at distance greater than 10kb from the TSS compared to Ifn alpha 
treatment.
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6.4.5.2 K562-stat2 treated with Ifn alpha for 30minutes and 6hrs
Untreated ChIP-seq data was not available therefore; we compared the 30min data to the 6hr 
data.
Looking at Figure 5-20, we see K562-stat2 treated with Ifn alpha for 6hr has slightly more 
peaks compared to the 30min. Increase treatment time corresponds to slight increase in ChIP- 
seq peaks.
Figure 5-21 shows in the less than 1kb distance from the TSS, Ifn alpha 30min has 37% and 
the 6hr has 28.9% TFBS. In the greater than 10kb distance from the TSS Ifn alpha treated 
30min has 44.4% and the 6hr has 46% TFBS.
We can deduce that more than 50% stat2 binding occurs in the less than 10kb distance from 
the TSS.
Ifn gamma does not activate STAT2 because it’s not part of the Ifn gamma -JAK-STAT 
pathway (Li, 2008).
6.5 A549-Gr treated with Dexamethasone (dex)
6.5.1 Background
Glucocorticoids used for the treatment of inflammatory disease. The glucocorticoid receptor 
(GR) is a receptor to which glucocorticoids bind. The immunosuppressive and anti­
inflammatory response is induced when glucocorticoid bind to GR which alters the 
transcription of numerous genes in leukocytes (Liberman et al., 2007).
The GR are located in the cytosol of the cell and when a glucocorticoid bind to the GR, it 
initiates two processes. The first process is the GR- glucocorticoids complex, which cause an
51 | P a g e
increase in the expression of anti-inflammatory proteins from the nucleus and the second 
process is the down-regulation of pro-inflammation proteins in the cytosol.
According to So et al. (2007), the glucocorticoids, which bind to GR, are generally located far 
from their target genes and they distributed equally upstream and downstream from their 
target genes.
GR in humans occurs in two isoforms namely GrP and Gra.
Dexamethasone is a synthetic glucocorticoids analog which is produced by the 
pharmaceutical industry to treat various disease e.g. inflammation (Liberman et al., 2007). 
When cells treated with dexamethasone, the dexamethasone will bind to GR, which then 
trigger the cells immunosuppressive and anti-inflammatory response. Dexamethasone is 
poorly metabolised and stays in the plasma longer when compared to the endogenous 
hormones. The endogenous hormones generally released in circadian cycle and are highly 
pulsatile whereas dexamethasone administered at a constant rate during treatment.
Dexamethasone treatment is also related to apoptosis and reducing the amount of T cells 
which is migrated to an inflammatory region.
According to Reddy et al. (2009), genes which were activated by the dexamethasone 
treatment, on the target genes the GR-dex complex were 11kb away from the TSS and for 
gene which were repressed the GR-dex complex was 146kb away from the TSS, both 
upstream relative to the target gene TSS.
F or GR not treated with dexamethasone the ChIP-seq signal was very weak and the treatment 
with dexamethasone resulted in an 11-fold increase in GR ChIP-seq signal (Reddy et al. 
2009).
6.5.2 Analysis
ChIP-seq data for A549-Gr, which received no dose, is not available therefore; we compared the 
ChIP-seq data for the various doses with each other. No information is available on the
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duration of the treatment and what time after treatment data was collected. It’s known that 
small amount of dexamethasone treatment can activate genes (Reddy et al., 2012).
Figure 5-15 indicates as the dose increase the number of ChIP-seq peaks increases. At a dose 
of 100nm, the number of ChIP-seq peaks is fewer compared to the 50nm dose.
From figure 5-16 we see in the less than 1kb distance from the TSS, dex 500pm has 11.3%, 
dex 5nm has 4.2%, dex 50nm has 6.6% and dex 100nm has 27.8% of its TFBS. At a distance 
greater than 10kb from the TSS, dex 500pm has 67.2%, dex 5nm has 75.9%, dex 50nm has 
71% and dex 100nm has 52.3% of its TFBS. It is noted for all samples, most of the binding 
occurred in the interval greater than 10kb from TSS. It seems A549-Gr treated with 
dexamethasone bind far away from the TSS.
Reddy et al. (2009) found 70% of genes had no Gr binding within a distance of 10kb from 
the TSS. Our results differ slightly where found fewer binding sites within the 10kb distance 
from the TSS and most of the TFBS at a distance greater than 10kb form the TSS.
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7 Conclusion
The case-control methodology for comparing the distance of the TFBS to the nearest TSS is 
very useful and informative. ChIP-Enrich is quick and easy to use and the histogram plots 
give gives a simple and quick overview of the distribution of distances of ChIP-seq peaks to 
the nearest TSS.
We observed that in the case of K562-cMyc there were a lesser percentage of TFBS, when 
the distance between the TFBS and the TSS was less than 1kb, compared to GM12878- 
cMyc. In the case of GM12878-CTCF and K562-CTCF, there was not much difference in 
the distribution of distances between ChIP-seq peaks and the nearest TSS. Thus our 
hypothesis of that there is a difference between the distance of the TFBS and the TSS in 
normal and abnormal cell type is partially correct.
In the case of K562-Irf1 treated with interferon gamma significant differences between the 
distribution of distance between the ChIP-seq peak and the TSS for the 30min and 6hr 
samples were seen.
In the case of dexamethasone, we can use the distance between the TFB and the TSS to 
determine the ideal dose.
ChIP-Enrich could be used as a screening method to get an overview of distribution of 
distance to nearest transcription factor binding. If there is a difference between the 
distributions of distances from ChIP-seq peak to nearest gene one could go further by 
looking at specific distances from a TSS where the differences exist. MEME could also be 
used to identify motifs and compare the case and control motifs. The next step would be to 
identify specific genes, which could explain the difference between the normal and case.
A shortcoming of our study was we did not look at the reasons as to why there is was a 
difference between the control distance and case distance binding.
If there is no difference between distributions of distance from ChIP-seq peak to the nearest 
TSS then one can assume the difference between the case and control is not caused by the 
distance between the TFBS and the nearest TSS.
The quality and accuracy of the ChIP-seq data is vital important because poor ChIP-seq data 
will give false results.
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Appendix A -  obtaining data and compare distance and binding order of transcription 
factors to the TSS.
In this section, we illustrate how to obtain and annotate data. We show how to calculate the 
distance between the transcription factor-binding site and transcriptions start site. We compare the 
binding order of the case and control binding site relative to the TSS.
1. Obtain data
1.1 Download the ChIP-seq data from the ENCODE website
All the data were downloaded from the following URL:
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgTfbsUniform/
1.2 Extract and uncompressing the compressed tar files
The command used to uncompressed and extract compressed tar files: 
tar -zxvf filename.tar.gz
1.3 Create a bed file from uncompressed narrow peak files
Using a python script to create a bed file, which contains 3 columns.
The first column will be the chromosome name, second column will be centre of the peak 
and the third column will be centre of peak + 1. We using the method which (Tallack et 
al., 2012) used. We are using the centre of the ChIP-seq peak as the point from which we 
will be measuring the distance to the TSS. The Bedtools (Quinlan and Hall, 2010) we will 
be using to join case with controls and with annotation data requires bed file to have the 
format of at least, chromosome, start and end coordinates.
2. Gene annotation data
The UCSC table browser was use to download the gene annotation data in a bed format file
for the entire human genome. The file contained Information on the gene name,
transcription start coordinate (TSS), TSS end coordinate and strand.
The gene annotation data was edited using a python script where only genes which
corresponded to the + strand was selected. The new gene annotation bed file contained the 
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chromosome name, TSS start, TSS start + 1. The reason for selecting only TSS and TSS +
1 was because our main goal was to calculate the distance between the centre of the ChIP- 
seq peak and the TSS. We used the TSS start point and the centre of the ChIP-seq peak as 
our reference points when calculating distance between TSS and TF.Gene annotation data 
for the + strand was only selected because the ChIP-seq data only had Information for the 
+ strand.
Procedure for obtaining gene annotation data in particular the TSS Information is as 
follows:
1. Go to: https://genome.ucsc.edu
2. Click on table browser
3. The table should have the following: 
group -  Genes and Gene prediction Tracks 
table -  refGene
output format -  selected fields from primary and related tables 
output file -  enter a name for output file
4. Click -  get output
5. Select fields you want e.g. name, chrom, txStart, txEnd
6. Click -  get output
2.1 mergeBed -  joining cancer-control cell types
mergeBed is a program which is part of the Bedtools suite of programs. The purpose of
mergeBed is to merge overlapping entries into a single interval reducing redundancy and
improving the quality of the data. A requirement of mergeBed is the data needs to be sorted
first based on chromosome then start. The general syntax for using sortBed and mergeBed
is as follows.
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2.2 sortBed -i inputFile.bed | mergeBed > out_sorted_merged.bed
The input bed file was sorted using the default setting for sortBed and then piped to
mergeBed and the output file will be a sorted file with overlapping entries merged.
2.3 closestBed -  joining case-control cell types
To join the case cell type with the control closestBed, was used. The closestBed program 
which will find the closest region between two bed files
2.4 closestBed -a cancerCell -b controlCell -  d -  t first > cancer_control.bed
-a indicates the name of the first file
-b indicates the name of second file
-d calculates the distance between the case and control cell, meaning calculate the distance 
between the first file (-a argument) and the second file (-b argument)
- t first -  return the first match in file b and ignore any other subsequent matches which 
might correspond to the same region in the first file.
The input to closestBed is two bed files each contain 3 column (chromosome, start, end) 
and the output of closestBed is a bedfile contains 7 columns. The first 3 columns will be 
ChIP-seq peak of cancer cell, the next 3 columns will be the closet control cell type ChIP- 
seq peak and the last column will contain distance between the centre of the cancer ChIP- 
seq peak and the centre of the closest control ChIP-seq peak. The distance is measured by 
the number bases between the two peaks.
2.5 closestBed -  joining case/control cell types with TSS
The procedure in step 5 joined the cancer cell type with the control cell type and to find the
closest TSS one need to join the case/control output from step 5 with the gene edited gene
annotation data. closestBed is used again this time the first input file argument, -a
case/control.bed (output from step 5) and the second input file argument, -  b will be the 
63 | P a g e
edited TSS data from step 4 above. The program closestBed will find the closest regions 
from the first three columns in the first input file and match the corresponding first three 
columns in the second input file. The output will consist of the closest TSS data for the 
case files because the first three columns from first input file correspond to the case 
coordinated.
The syntax for the closestBed command:
closestBed -a case_control.bed -b edited_TSS.bed -d -t first > 
cancer_control_TSS.bed
The output of the above closestBed will have 11 columns with the additional columns the 
nearest TSS to the cancer cell_type and the last column will be the distance between the 
centre of the ChIP-seq peak of the cancer cell type and TSS, which is measured in number 
of bases.
3. psT Distribution
To gain a better understanding of the binding of the case cell type vs. control cell type vs. 
TSS we introduce the psT distribution nomenclature.
The psT distribution allow us to determine the binding order of the case cell type relative to 
the control cell type as well as the binding order of the case/control cell type relative to the 
TSS. We define upstream as the TFBS that occur before the TSS and downstream as TFBS 
that occur after the TSS.
The psT distribution naming convention is as follows:
p -  TF used in first (primary) argument in closestBed (correspond -a  value in closestBed) 
s- TF used in second (secondary) argument in closestBed (correspond -b  value in 
closestBed)
T -  Refers to the TSS
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The various combinations for p, s and T are as follows. 
spT, psT, Tsp, Tps, pTs, sTp
3.1 Binding order of p, s and T
When looking at the binding order we would like to know when p is in front of s, and when 
s is in front of p. When we used the word “in front” we are comparing the centre of the 
ChIP-seq peaks of s and p; p in front of s means on a linear scale the location of the CHiP- 
seq peak of p has a smaller coordinate than s. It is a given p and s should be on the same 
chromosome.
E.g., if  p had bed coordinates chr 10 100(peakcentre) and s bed coordinates chr 10 450 then 
p would be in front of s because a 100 is less than 450. When looking at the order (binding 
of p relative to s) we also take into account whether the binding is upstream or 
downstream. We consider the binding of p and s relative to the TSS. Upstream defined as 
the location in front of the TSS with coordinates less than the TSS. Downstream defined as 
the location after the TSS, those with coordinates greater than the TSS.
3.2 p, s and TSS binding combinations
The binding of cases cell type and control cell type relative to TSS can occur in the 
following combination. Let assume p = case cell type, s= control cell type and T= TSS and 
the same TF is used in both cell type. Since the TF is the same for both cell types, we will 
refer to the cell types to avoid confusion or where the TF is different between the cell types 
we will refer to the TF.
psT -  s (control cell type) binds closer to the TSS and p (case cell type) binds further away 
from TSS. Relative to the TSS s is in front of p. Both case and control binds upstream of
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TSS with control binding closer to TSS and cancer cell type further away from TSS 
spT - both case and control binds upstream of TSS with caser binding closer to TSS and 
control cell type further away from TSS
Tps - both cancer and control binds downstream of TSS with cancer binding closer to TSS 
and control cell type further away from TSS
Tsp - both cancer and control binds downstream of TSS with control binding closer to TSS 
and cancer cell type further away from TSS
pTs -  cancer cell type binds upstream and control is binding downstream with TSS in the 
middle
sTp -  control cell type binds upstream and cancer is binding downstream with TSS in the 
middle
We can also infer from the psT binding order whether cancerous cell type or normal type 
tend to bind more closely to the TSS and whether its preferred binding is upstream or 
downstream relative to the TSS.
A summary of the binding order of p and s relative to TSS shown below.
binding order Upstream (before TSS) Downstream (after TSS)
p in front of s psT or pTs Tps
s in front of p spT or sTp Tsp
Table 1 p and s upstream and downstream binding order relative to TSS.
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A summary of the closeness of p and s relative to T shown below
closeness to TSS Upstream (before TSS) Downstream(after TSS)
p closer to T spT or pTs Tps or sTp
s closer to T psT or sTp Tsp or pTs
Table 2 closeness of p and s relative to the TSS
Dividing data into intervals
To compare bindings we normalized the two datasets.
After normalization, we summed all the values in the table and in each interval; we 
expressed each value as a percentage of the total, which allowed us to compare values.
The final dataset from closestBed was divided into 3 groups.
1. psT peak distribution
The data was divided into intervals based on the distance between the two peaks i.e. the 
centre of the peak of the first input file (p) and the centre of the peak of the second input 
file (s).
We divide this group further into two intervals. The first interval is where the distance 
between the peaks of p and s is less than 2kb and the second interval is where the distance 
between the peaks of p and s is greater or equal to 2kb. In this group, we only focussing on 
the distance between the peaks of p and s.
E.g., psT peak distances less 2kb would mean the distance between the peaks of p and s is 
less than 2000 bases.
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2. psT TSS distribution
The data was divided into intervals based on the distance between the TSS and the peak of 
p or s.
We divide this group further into two intervals. The first interval is where the distance 
between the TSS and peaks of p or s is less than 2kb and the second interval is where the 
distance between the TSS and the peaks of p or s is greater or equal to 2kb. In this group, 
we only focussing on the distance between the TSS and the peak of p or s.
E.g., psT TSS-TF distance less or equal to 2kb would mean the distance between either the 
centre of the peak of p or s and the TSS is less than 2000 bases.
3. psT Global distribution
The psT global distribution looks at the genome wide ordering of p and s. The data is not divided 
into any intervals.
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4. Example of Results
4.1 K562-Gm12878- cMyc
The binding distribution K562 and GM12878 cell types with particular reference to the TF 
cMyc.
4.2 Number of cMyc peaks for K562 and GM12878
A summary of the number of peaks found for K562 and GM12878 cell types for the TF
cMyc shown.
cMyc(no of peaks )
K562 11738
GM12878 3690
Table 3 K562 and GM12878 number of cMyc peaks
A graphical display of the number of peaks shown below.
14000
12000
10000
8000
6000
4000
2000
0
cMyc(no of peaks )
K562 GM12878
Figure 1 Number of cMyc peaks
Figure 1 indicates there is almost 3 times more cMyc binding sites in the K562 cell type as 
compared to the GM12878 cell type.
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4.3 Genome-wide distribution for K562-cMyc and GM12878-cMyc
K562cMyc - GM12878- cMyc global distribution
%_psT %_spT %_Tps %_Tsp %_pTs %_sTp
Figure 2 global psT distribution for p and s relative to TSS. All values in percentage. p - K562cMyc, 
s- GM878-cMyc
p p in front s s in front p p close to T s close to T
\ 1 s
Up
stream
Down
stream
Up
stream
Down
stream
Up
stream
Down
stream
Up
stream
Down
stream
UtaGm12878Cmyc/
UtaGm12878Cmyc 48.6 51.4 0.0 0.0 0.0 51.4 48.6 0.0
UtaK562Cmyc/
UtaK562Cmyc 52.9 47.1 0.0 0.0 0.0 47.1 52.9 0.0
UtaK562Cmyc/
UtaGm12878Cmyc 28.7 21.9 41.3 8.1 32.1 28.5 19.0 20.4
Table 4 global psT Genome distribution (p-K562, s-GM12878, T-TSS) for cMyc (values in percentage)
Discussion on Table 4
UtaGm12878Cmyc_UtaGm12878Cmyc
The global psT distribution for GM12878-cMyc can be summarized by psTps.
In this case p equals s which is equal to GM12878-cMyc (p=s=GM12878-cMyc). We can 
see that 48.6 % of the time in GM12878 cMyc binds upstream and the 51.4% downstream 
with respect to TSS.
UtaK562Cmyc_UtaK562Cmyc
Since p=s=K562-cMyc the psT pattern would be pTp. We see from Table cMyc in K562 
binds 52.9% upstream and 47.1 % downstream with respect to the TSS. 
UtaK562Cmyc_UtaGm12878Cmyc
The psT distribution for K562-GM12878-cMyc can be summarized by: spTps
This means cMyc in the K562 cell type tend to bind closer to the TSS both upstream and
downstream compared to cMyc in the GM12878 cell type.
When comparing the binding of K562-cMyc and GM12878-cMyc we notice K562-cMyc
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has more binding sites upstream compared to GM12878cMyc.
4.4 psT distribution where TF (p)-TF(s) distance less or equal to 2kb
P
p in front s s in  front p p  close to T s close to T
^  S U p
stream
D ow n
stream
U p
stream
D ow n
stream
U p
stream
D ow n
stream
U p
stream
D ow n
stream
U taG m 12878C m yc/
U taG m 12878C m yc 48.6 51.4 0.0 0.0 0.0 51.4 48.6 0.0
U taK 562C m yc/
U taK 562Cm yc 52.9 47.1 0.0 0.0 0.0 47.1 52.9 0.0
U taK 562C m yc/
U taG m 12878C m yc 29.5 20.2 32.3 17.9 29.4 23.9 22.3 24.4
Table 5 psT distribution peak distance less 2kb (p-K562, s-GM12878, T-TSS) for cMyc (values in percentages)
Discussion on Table 5 
UtaGm12878Cmyc_UtaGm12878Cmyc
The psT distribution for GM12878 is pTp with 48.6% binding occurring upstream and 
51.4% of binding occurring downstream.
UtaK562Cmyc_UtaK562Cmyc
Since p=s=K562-cMyc the psT pattern would be pTp. We see from Table Table cMyc in 
K562 binds 52.9% upstream and 47.1% downstream with respect to the TSS.
UtaK562Cmyc_UtaGm12878Cmyc
The psT distribution for K562-GM12878-Cmyc can be summarized by: spTps
This means cMyc in the K562 cell type tend to bind closer to the TSS both upstream and
downstream compared to cMyc in the GM12878 cell type.
4.5 psT distribution where TF (p)-TF(s) distance greater than 2kb
P p in front s s in  front p p  close to T s close to  T
O  s U p
stream
D ow n
stream
U p
stream
D ow n
stream
U p
stream
D ow n
stream
U p
stream
D ow n
stream
U taG m 12878C m yc
U taG m 12878C m yc 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
U taK 562Cm yc 
U taK 5 62Cm yc 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
U taK 562Cm yc
U taG m 12878C m yc 28.1 22.9 47.0 1.9 33.5 30.8 17.3 18.4
Table 6 psT distribution peak distance greater 2kb (p-K562, s-GM12878, T-TSS) for cMyc (values in percentage)
Discussion on Table 6
UtaGm12878Cmyc_UtaGm12878Cmyc
In the interval greater than 2kb we expect the distance between the peaks to be 0 because 
p=GM12878-cMyc and s=GM12878-cMyc.
UtaK562Cmyc_UtaK562Cmyc
In the interval greater than 2kb we expect the distance between the peaks to be 0 because
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p=K562-cMyc and s=K562-cMyc.
UtaK562Cmyc_UtaGm12878Cmyc
The psT distribution summary for K562-GM12878-cMyc is: spTps
This is in agreement with the results obtained thus far of K562-cMyc binding closer to TSS 
both upstream and downstream.
4.6 psT TSS-TF distance less or equal to 2kb
p p in front s s in front p p close to T s close to T
< 1  s Up
stream
Down
stream
Up
stream
Down
stream
Up
stream
Down
stream
Up
stream
Down
stream
UtaGm12878Cmyc/
UtaGm12878Cmyc 42.4 57.6 0.0 0.0 0.0 57.6 42.4 0.0
UtaK562Cmy/
UtaK562Cmyc 52.3 47.7 0.0 0.0 0.0 47.7 52.3 0.0
UtaK562Cmyc/
UtaGm12878Cmyc 32.1 20.2 38.5 9.2 31.4 26.8 18.7 23.1
Table 7 psT distribution TSS-peak distance less 2kb (p-K562, s-GM12878, T-TSS) for cMyc (values in percentage)
Discussion on Table 7 
UtaGm12878Cmyc_UtaGm12878Cmyc
The psT distribution for GM12878 is pTp with 42.4 % binding occurring upstream and
57.6 % of binding occurring downstream.
UtaK562Cmyc_UtaK562Cmyc
Since p=s=K562-cMyc the psT pattern would be pTp. We see from Table Table cMyc in 
K562 binds 52.3% upstream and 47.7 % downstream with respect to the TSS.
UtaK562Cmyc_UtaGm12878Cmyc
The psT distribution for K562-GM12878-Cmyc can be summarized by: spTps
This means cMyc in the K562 cell type tend to bind closer to the TSS both upstream and
downstream compared to cMyc in the GM12878 cell type.
4.7 ^ psT TSS-TF distance greater than 2kb________________________ ________________
p p in  fron t s s in  front p p  close to T s close to T
s U pstream
D ow n
stream
U p
stream
D ow n
stream
U p
stream
D ow n
stream
U p
stream
D ow n
stream
U taG m 12878C m yc/
U taG m 12878C m yc 55.7 44.3 0.0 0.0 0.0 44.3 55.7 0.0
U taK 562C m yc/
U taK 562Cm yc 53.3 46.7 0.0 0.0 0.0 46.7 53.3 0.0
U taK 562C m yc/
U taG m 12878C m yc 25.8 23.3 43.8 7.2 32.7 30.1 19.3 18.0
Table 8 psT distribution TSS-peak distance greater 2kb (p-K562, s-GM12878, T-TSS) for cMyc (values in 
percentage)
Discussion on Table 8
UtaGm12878Cmyc_UtaGm12878Cmyc
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The psT distribution for GM12878 is pTp with 55.7 % binding occurring upstream and
44.3 % of binding occurring downstream.
UtaK562Cmyc_UtaK562Cmyc
Since p=s=K562-cMyc the psT pattern would be pTp. We see from Table Table cMyc in 
K562 binds 53.3% upstream and 46.7 % downstream with respect to the TSS.
UtaK562Cmyc_UtaGm12878Cmyc
The psT distribution for K562-GM12878-Cmyc can be summarized by: spTps
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Appendix B -  Quality control of CHiP-seq data
1. Summary statistics of raw sequence data- GM12878-cmyc (control)
gm12878_cmyc_sample.fastq FastQC Report
Summary
Basic Statistics 
Per base sequence quality 
Per sequence quality scores 
Per base sequence content 
Per sequence GC content 
Per base N content 
Sequence Length Distribution 
Sequence Duplication Levels 
Overrepresented sequences 
Adapter Content
Kmer Content
Basic Statistics
Measure 
Filename 
File type 
Encoding 
Totl Sequences 
Sequences flagged as poor 
quality 0 Sequence length
%GC
Value
gm 12878_cmyc_sample.fastq 
Conventional base calls 
Sanger / Illumina 1.9 
16954037
33
41
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© Per base sequence quality
Per sequence quality scores
Per base sequence content
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Per sequence GC content
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Per base N content
N cement across -ail bases
1 CD 
30 
60 
70 
SO 
50 
40  
30 
20 
10 
0
%N
1 2 3 4 5 8 7 B 3  10 11 12 13 14 15 1 8 17 18 19 20 21 22 23 24 25 28 27 23 29 30 31 32 33
^osrson in read (bp)
Sequence Length Distribution
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Sequence Duplication Levels
Overrepresented sequences
No overrepresented sequences
Adapter Content
Adar**
too
9 C
eo
70
eo
90
40
30
20
10
0
illum Via Un(va*»«l Ao-jpio- 
HlurrMn* 8n>4ll n NA 9 ' AcJatriBr
T < a n tp n i« m  b « t|M in r«
s*X ll>  Pm «* MN*A AckBOat
I 9  3 4 9  A 7  A P I Q l «  18 13 14 19 10 17 l A  I P  8 0  01
Portion In lead Ibo)
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Kmer Content
Sequence Count PValue Obs/Exp Max Max Obs/Exp Position
TATGCCG 355 1.0552722E-6 6.847477 16
GCTCGTA 285 1.28397E-4 6.6327167 11
CTCGTAT 390 2.0644582E-4 5.539706 12
GATCGGA 345 0.001500593 5.4769382 1
Produced by FastQC (version 0.11.5)
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©
©
©
©
©
©
©
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2. Summary statistics of raw sequence data- K562-cMyc (case)
k562_cmyc_sample.fastq FastQC Report
Summary
© Basic Statistics 
Per base sequence quality 
Per sequence quality scores 
Per base sequence content 
Per sequence GC content 
Per base N content 
Sequence Length Distribution 
Sequence Duplication Levels 
Overrepresented sequences 
Adapter Content
W Basic Statistics 
Measure
Filename 
File type 
Encoding 
Total Sequences 
length 
%GC
Value
k562_cmyc_sample.fastq 
Conventional base calls 
Sanger / Illumina 1.9
13388470 Sequences flagged as poor quality 0 Sequence
35
44
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Per sequence quality scores
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Per base sequence content
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oo
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30
90
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f 'o n t t e n  h  m m i  Ibp )
Per sequence GC content
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Per base N content
N contort a:ros5 a* booes100
90
80
70
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40 
90 
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1 9 8 4 9 6 7 6 9  10 I t  12 (9 14 16 17 to  19 90 91 92 29 94 99 98 97 96 99 80 
Pui-lion in road |bp)
81 19 88 84 39
83 | P a g e
Sequence Length Distribution
Sequence Duplication Levels
Overrepresented sequences
No overrepresented sequences
84 | P a g e
Adapter Content
Vi Adaptor100
90
60
TO
60
30
40
90
20
10
0
Itunlna U nM nal Ao-artor 
llomina $m«il RHA y  Adopter
f ic i i f a  T t jnscos-ioe b©ouc<x«
SOLID Snull FA4A Adaptr-
1 8 9 4 5 6  7 0 9  10 11 18 19 14 15 IQ 17 IQ 19 20 21 
Poilloo In n i« i |bc)
28 89
Kmer Content
Sequence Count PValue Obs/Exp Max Max Obs/Exp Position 
GATCGGA 3930 0.0 20.222609 1
GCTCGTA 5315 0.0 14.255909 11
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CTCGTAT 5355 0.0 14.151802 12
TATGCCG 5455 0.0 13.879352 16
TCGTATG 5440 0.0 13.825324 13
CGTATGC 5500 0.0 13.811094 14
AGCTCGT 5480 0.0 13.63799 10
ATGCCGT 5560 0.0 13.305397 17
GCCGTCT 5550 0.0 13.303135 19
TGCCGTC 5660 0.0 12.941986 18
GAGCTCG 5870 0.0 12.829101 9
CCGTCTT 5830 0.0 12.817245 20
CGTCTTC 5850 0.0 12.458263 21
GTATGCC 6320 0.0 12.2975235 15
CGGAAGA 6445 0.0 12.218935 4
TCGGAAG 6560 0.0 12.203339 3
ATCGGAA 6535 0.0 12.161415 2
GAAGAGC 8015 0.0 9.62678 6
AGAGCTC 8085 0.0 9.367284 8
Sequence Count PValue Obs/Exp Max Max Obs/Exp Position
GTCTTCT 8680 0.0 8.7527685 22
Produced by FastQC (version 0.11.5)
3. Comparing K562-cMyc and GM12878-cMyc signal intensity at various 
intervals around the TSS
Below is a summary of the signal intensity and count of the ChIP-seq peaks for K562-cMyc and 
GM12878 at various intervals around the TSS.
Summary of results
G 12878-cM yc
Before TSS
Interval Ave signal intensity Count
Average signal intensity in (0-0.1] 13.691 6
Average signal intensity in (0.1-1] 6.926 54
Average signal intensity in (1-5] 2.617 240
Average signal intensity in (5-10] 2.359 300
Average signal intensity in(10-20] 2.282 600
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After TSS
Interval Ave signal intensity Count
Average signal intensity in (0-0.1] 15.484 6
Average signal intensity in (0.1-1] 9.042 54
Average signal intensity in (1-5] 2.845 240
Average signal intensity in (5-10] 2.579 300
Average signal intensity in(10-20] 2.44 600
K562-cM yc
Before TSS
Interval Ave signal intensity Count
Average signal intensity in (0-0.1] 3.045 6
Average signal intensity in (0.1-1] 3.297 54
Average signal intensity in (1-5] 2.503 240
Average signal intensity in (5-10] 2.21 300
Average signal intensity in(10-20] 2.133 600
After TSS
Interval Ave signal intensity Count
Average signal intensity in (0-0.1] 2.99 6
Average signal intensity in (0.1-1] 3.042 54
Average signal intensity in (1-5] 2.785 240
Average signal intensity in (5-10] 2.461 300
Average signal intensity in(10-20] 2.333 600
GM12878-cMyc-  
from  above intervals. 
A verages for both  
upstream  and  
dow nstream
Interval Ave signal Intensity Count
87 | P a g e
Average signal intensity in (0-0.1] 14.5875 12
Average signal intensity in (0.1-1] 7.984 108
Average signal intensity in (1-5] 2.731 480
Average signal intensity in (5-10] 2.469 600
Average signal intensity in(10-20] 2.361 1200
K562-cMyc-  from  
above intervals. 
A verages for both  
upstream  and  
dow nstream
Interval Ave signal Intensity Count
Average signal intensity in (0-0.1] 3.0175 12
Average signal intensity in (0.1-1] 3.1695 108
Average signal intensity in (1-5] 2.644 480
Average signal intensity in (5-10] 2.3355 600
Average signal intensity in(10-20] 2.233 1200
Global -  [0-20kb] 
distance from the TSS
Before TSS
Ave signal Intensity Count
G12878-cMyc -Global Average signal intensity 2.634 1200
K562-cMyc -Global Average signal intensity 2.283 1200
Ave signal Intensity Count 
2.918 1200
2.491 1200
Global-average 
intensity in the [-20kb- 
20kb] interval from 
the TSS
After TSS
G12878-cMyc -Global Average signal intensity 
K562-cMyc -Global Average signal intensity
Ave signal Intensity Count
G12878-cMyc -Global Average signal intensity 2.776 2400
K562-cMyc -Global Average signal intensity 2.389 2400
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4. Welch, z-Test and Wilcox statistics
As shown in section 3, we calculated the signal intensity from the TSS for both K562-cMyc and 
GM12878 in the [0-0.1kb], (0.1 -1kb], (1-5kb], (5-10kb] and (10-20kb] interval from the TSS. The 
left hand side of the interval correspond to the minimum distance between peak and the TSS. The 
right hand side correspond to the maximum distance between the peak and the TSS.
For interest sake, we used the z-Test, Welch and Wilcox test to compare the mean between the two 
samples to determine if the mean between to the samples are statistically different.
4.1 Welch statistics
Upstream:
1. 0 - 0.1k b upstream
Welch Two Sample t-test
data: gm12_1m and K562_01m 
t = 3.3945, df = 23.787, p-value = 0.00241
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval:
1.520214 6.241762 
sample estimates: 
mean of x mean of y
6.925720 3.044732
2. 0.1-1 kb upstream
Welch Two Sample t-test
data: gm12_1m and K562_1m 
t = 4.0272, df = 60.996, p-value = 0.0001587
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval:
1.826764 5.429881 
sample estimates: 
mean of x mean of y
6.925720 3.297398
3. 1-5 kb upstream
Welch Two Sample t-test
data: gm12_5m and K562_5m 
t = 1.2298, df = 477.97, p-value = 0.2194
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval:
-0.06876499 0.29884180
sample estimates: 
mean of x mean of y 
2.617382 2.502343
4. 5-10 kb upstream
Welch Two Sample t-test
data: gm12_10m and K562_10m 
t = 2.5005, df = 597.66, p-value = 0.01267
alternative hypothesis: true difference in means is not equal to 0
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95 percent confidence interval:
0.0319532 0.2658498 
sample estimates: 
mean of x mean of y 
2.358797 2.209896
5. 10-20 kb upstream
Welch Two Sample t-test
data: gm12_20m and K562_20m 
t = 3.8649, df = 1196.6, p-value = 0.0001171
alternative hypothesis: true difference in means is not equal to 
95 percent confidence interval:
0.0733555 0.2246175 
sample estimates: 
mean of x mean of y 
2.281613 2.132626
Downstream:
1. 0-0.1 kb downstream
Welch Two Sample t-test
Welch Two Sample t-test
data: gm12_01m and K562_01m 
t = 1.9173, df = 5.1825, p-value = 0.1113
alternative hypothesis: true difference in means is not equal to 
95 percent confidence interval:
-3.477667 24.770342 
sample estimates: 
mean of x mean of y 
13.691070 3.044732
2. 0.1-1kb downstream
Welch Two Sample t-test
data: gm12_1m and K562_1m 
t = 4.0272, df = 60.996, p-value = 0.0001587
alternative hypothesis: true difference in means is not equal to 
95 percent confidence interval:
1.826764 5.429881 
sample estimates: 
mean of x mean of y
6.925720 3.297398
3. 1-5 kb downstream
Welch Two Sample t-test
data: gm12_5m and K562_5m 
t = 1.2298, df = 477.97, p-value = 0.2194
alternative hypothesis: true difference in means is not equal to 
95 percent confidence interval:
-0.06876499 0.29884180
sample estimates: 
mean of x mean of y 
2.617382 2.502343
0
0
0
0
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4. 5-10 kb downstream
Welch Two Sample t-test
data: gm12_10m and K562_10m 
t = 2.5005, df = 597.66, p-value = 0.01267
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval:
0.0319532 0.2658498 
sample estimates: 
mean of x mean of y 
2.358797 2.209896
5. 10-20 kb downstream/8 
Welch Two Sample t-test
data: gm12_20m and K562_20m 
t = 3.8649, df = 1196.6, p-value = 0.0001171
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval:
0.0733555 0.2246175 
sample estimates: 
mean of x mean of y 
2.281613 2.132626
4.2 z-Test
1.0 0-0.1 kb upstream (small number of samples therefore did t-Test) 
t-Test: Two-Sample Assuming Unequal Variances
Variable 1 V ariable 2
Mean
Variance
Observations
Hypothesized Mean
Difference
Df
t Stat
P(T<=t) one-tail 
t Critical one-tail 
P(T<=t) two-tail 
t Critical two-tail
1.917303653
0.056659895
2.015048373
0.113319789
2.570581836
13.69106965 3.0447323
181.6832121 3.316008289
6
0
5
6
2. 0.1-1 kb upstream
z-Test: Two Sample for Means
91 | P a g e
Variable 1 V ariable 2
Mean 6.92572045 3.297398215
Known Variance 40.74137 34.36008
Observations 54 54
Hypothesized Mean Difference 0
Z 3.07665337
P(Z<=z) one-tail 0.00104669
z Critical one-tail 1.64485363
P(Z<=z) two-tail 0.00209339
z Critical two-tail 1.95996398
3. 1-5kb upstream
z-Test: Two Sample for Means
V ariable
1 Variable 2
Mean 2.617382 2.50336227
Known Variance 1.042287 1.087176
Observations 240 240
Hypothesized Mean
Difference 0
Z 1.210457
P(Z<=z) one-tail 0.113052
z Critical one-tail 1.644854
P(Z<=z) two-tail 0.226104
z Critical two-tail 1.959964
4. 5-10kb upstream
z-Test: Two Sample for Means
V ariable Variable
1 2
Mean 2.358797 2.209896
Known Variance 0.544556 0.519225
Observations 300 300
Hypothesized Mean
Difference 0
Z 2.500539
P(Z<=z) one-tail 0.0062
z Critical one-tail 1.644854
P(Z<=z) two-tail 0.0124
z Critical two-tail 1.959964
5. 10-20kb upstream
z-Test: Two Sample for Means
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Variable
1
Variable
2
Mean 2.281613 2.132626
Known Variance 0.460907 0.430704
Observations 600 600
Hypothesized Mean Difference 0
Z 3.864869
P(Z<=z) one-tail 5.56E-05
z Critical one-tail 1.644854
P(Z<=z) two-tail 0.000111
z Critical two-tail 1.959964
Downstream
1. 0-0.1 kb downstream (small number of samples therefore did t-Test) 
t-Test: Two-Sample Assuming Unequal Variances
V ariable 1
V ariable
2
Mean 15.48434 2.989824
Variance 242.5302 3.082639
Observations 6 6
Hypothesized Mean Difference 0
df 5
t Stat 1.952852
P(T<=t) one-tail 0.054137
t Critical one-tail 2.015048
P(T<=t) two-tail 0.108274
t Critical two-tail 2.570582
2. 0.1-1 kb downstream
z-Test: Two Sample for Means
Variable Variable
1 2
Mean 9.041993 3.041723
Known Variance 77.36758 2.667685
Observations 54 54
Hypothesized Mean Difference 0
z 4.928639
P(Z<=z) one-tail 4.14E-07
z Critical one-tail 1.644854
P(Z<=z) two-tail 8.28E-07
z Critical two-tail 1.959964
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3. 1-5kb downstream
z-Test: Two Sample for Means
Variable
1 Variable 2
Mean 2.844631 2.784962181
Known Variance 1.759337 1.817623
Observations 240 240
Hypothesized Mean Difference 0
z 0.488758
P(Z<=z) one-tail 0.312507
z Critical one-tail 1.644854
P(Z<=z) two-tail 0.625013
z Critical two-tail 1.959964
4. 5-10kb downstream
z-Test: Two Sample for Means
V ariable
1
Variable
2
Mean 2.578851 2.461215
Known Variance 1.053939 1.064203
Observations 300 300
Hypothesized Mean Difference 0
z 1.399987
P(Z<=z) one-tail 0.080759
z Critical one-tail 1.644854
P(Z<=z) two-tail 0.161517
z Critical two-tail 1.959964
5. 10-20kb downstream 
z-Test: Two Sample for Means
Variable
1
V ariable
2
Mean 2.440163 2.33338
Known Variance 0.803378 0.851494
Observations 600 600
Hypothesized Mean Difference 0
z 2.033266
P(Z<=z) one-tail 0.021013
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z Critical one-tail 
P(Z<=z) two-tail 
z Critical two-tail
1.644854
0.042026
1.959964
4.3 Wilcox Test
Upstream
1. 0-0.1kb upstream
Wilcoxon rank sum test
data: aa$gm_0.1m and aa$k562_0.1m 
W = 28, p-value = 0.132
alternative hypothesis: true location shift is not equal to
2. 0.1-1kb upstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_1m and aa$k562_1m 
W = 2079, p-value = 0.0001375
alternative hypothesis: true location shift is not equal to
3. 1-5kb upstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_5m and aa$k562_5m 
W = 34125, p-value = 0.000458
alternative hypothesis: true location shift is not equal to
4. 5-10kb upstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_10m and aa$k562_10m 
W = 58063, p-value = 7.622e-10
alternative hypothesis: true location shift is not equal to
5. 10-20kb upstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_20m and aa$k562_20m 
W = 231370, p-value < 2.2e-16
alternative hypothesis: true location shift is not equal to
Downstream 
1. 0-0.1kb downstream
0
0
0
0
0
Wilcox on rank sum test 
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data: aa$gm_0.1p and aa$k562_0.1p 
W = 28, p-value = 0.132
alternative hypothesis: true location shift is not equal to
2. 0.1-1kb downstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_1p and aa$k562_1p 
W = 2175, p-value = 1.07e-05
alternative hypothesis: true location shift is not equal to
3. 1-5kb downstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_5p and aa$k562_5p 
W = 31923, p-value = 0.03988
alternative hypothesis: true location shift is not equal to
4. 5-10kb downstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_10p and aa$k562_10p 
W = 55282, p-value = 1.281e-06
alternative hypothesis: true location shift is not equal to
5. 10-20kb downstream
Wilcoxon rank sum test with continuity correction
data: aa$gm_20p and aa$k562_20p 
W = 221490, p-value = 4.772e-12
alternative hypothesis: true location shift is not equal to
0
0
0
0
0
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